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Abstract 
 
Introduction: Nocturnal Frontal Lobe Epilepsy (NFLE) is characterized by onset during infancy 
or childhood with persistence in adulthood, family history of similar nocturnal episodes 
simulating non-REM parasomnias (sleep terrors or sleepwalking), general absence of 
morphological substrates, often by normal interictal electroencephalographical recordings 
(EEGs) during wakefulness. Neurological examination is generally normal. A symptomatic 
aetiology is present in only 13% of NFLE cases, whereas the vast majority remains cryptogenic. 
A family history of epilepsy may be present and a clear Mendelian autosomal dominant 
inheritance has been described in some families. Recent studies indicate the involvement of 
neuronal nicotinic acetylcholine receptors (nAChRs) in the molecular mechanisms of NFLE. In 
particular, mutations in the genes encoding for the α4 (CHRNA4) and ß2 (CHRNB2) subunits of 
the nAChR induce changes in the biophysical properties of nAChR, resulting generally in a 
“gain of function”. Preclinical studies report that activation of a nuclear receptor called type 
peroxisome proliferator-activated receptor (PPAR-α) by endogenous molecules or by 
medications (e.g. fenofibrate) reduces the activity of the nAChR and, therefore, may decrease the 
frequency of seizures. Thus, we hypothesize that negative modulation of nAChRs might 
represent a therapeutic strategy to be explored for pharmacological treatment of this form of 
epilepsy, which only partially responds to conventional antiepileptic drugs. In fact, 
carbamazepine, the current medication for NFLE, abolishes the seizures only in one third of the 
patients. 
The aim of the project is:  
 to verify the clinical efficacy of adjunctive therapy with fenofibrate in pharmacoresistant 
NFLE and ADNFLE patients; focousing on the analysis of the polysomnographic action of 
the PPAR- agonist (fenofibrate). 
Furthermore, to demonstrate the subtended mechanism of efficacy by means of 
electrophysiological and behavioral experiments in an animal model of the disease: particularly, 
transgenic mice carrying the mutation in the nAChR 4 subunit (Chrna4S252F) homologous to 
that found in the humans. Considering that neocortical networks and thalamocortical cells have a 
major role in the generation of ictal activity and synchrony, the neurons located in these two 
regions (i.e. frontal cortex and thalamus) has been recorded by performing patch-clamp 
experiments in brain slices. Behavioral experiments and subdural EEG also been performed to 
monitor the efficacy of PPAR- α agonists on spontaneous or evoked seizures.  
Given that PPAR-α agonists (e.g. fenofibrate) are already clinically utilized for lipid 
 4 
metabolism disorders, the study provides new evidence for a novel therapeutic indication of 
these drugs, and be suggestive of a promising therapeutic avenue in the treatment of 
NFLE\ADNFLE. 
 
Methods:  
1) 16 patients affected by ADFNLE & FNLE and pharma-coresistant under treatment with 
several anti-epileptic drugs will be selected among 2756 outpatients attending the Epilepsy 
Diagnostic and Treatment Centre of Cagliari (Italy). After informed consent is obtained, patients 
had been enrolled into the protocol and clinical and instrumental recognition applied before add-
on therapy with fenofibrate.  
Fenofibrate is a long time used drug aimed at dismetabolic disease of the lipids, which has been 
recently shown to be an agonist at the peroxisome-proliferator-activated receptor (PPAR-alfa), a 
family of nuclear receptor transcription factors, which in turn modulates the nAChR involved in 
ADFNLE.  
2) The EEG methods employed include repeated Video- EEG (VEEG), twenty-four hours 
Video-digital EEG, scrutiny of several previously recorded EEGs, all of them recorded in digital 
format. Digital recordings acquired in 11 FNLE epileptic subjects after 6 months of adjunctive 
fenofibrate therapy will be compared with baaseline.  
 
Expected Results: The present study, based both on recent advances in basic research issued by 
our laboratories and clinical observations described in recent studies, pursued a pragmatic 
investigation on such new categories of antiepileptic drugs based on nicotinic role in epilepsy.   
It is expected:  
1) to obtain a significant reduction of seizure frequency in a selected population affected by 
FNLE non responders to traditional therapy by means of adjunctive therapy with fenofibrate.  
2) to demonstrate the efficacy of ppar-alpha agonist in acute and chronic administration of 
fenofibrate in a farmacological animal models whitihin in vivo and in vitro experiments,  
3) to demonstrate the efficacy of ppar-alpha agonist in chronic administration of fenofibrate in a 
genetic mouse model of NFLE in vivo & in vivo experiments. 
 
Discussion and Conclusion: Hence, if treatment necessity is undoubtful to eliminate nocturnal 
seizures and turn sleep into a restful experience (excessive daytime sleepiness is a frequent 
symptom in NFLE), the pharmacological approach remains empirical based on a restricted 
spectrum of classical antiepileptic agents. Carbamazepine, the most efficacious drug in NFLE, 
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completely abolishes the seizures in ~20% of the cases and reduces the seizures in another 48%, 
leaving approximately one third of patients resistant to therapy. The recently discovered novel 
mechanism of regulation of nAChRs by PPAR-α may represent a new therapeutic avenue 
formedications aimed at diseases such as NFLE and ADNFLE, where “a gain of function” of 
nAChR is responsible for the cardinal symptoms. The use of available animal models of 
ADNFLE, together with advanced neurophysiological techniques in humans, offered an 
extraordinary opportunity to develop an important therapeutic strategy that, noteworthy, may 
rely on drugs already clinically utilized in humans. 
 
 The present project is realised in cooperation with the Medicine Sleep Centre of the 
University of Parma and the Medicine Sleep Centre of Cagliari.  
 
Financed by National Grant PRIN 2009.  
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Rationale of the work.  
 
Epilepsy is a common neurological disorder affecting1% of the population worldwide. Over the 
past decade, several idiopathic epilepsies have been identified that show single-gene inheritance, 
such as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Considerable clinical 
and genetic evidences now provide a strong link between the ADNFLE syndrome and mutations 
located within the second pore-forming transmembrane domain of the nAchR sub-units. Given 
the similarities in clinical symptoms, it has been suggested that a common functional anomaly of 
mutant α4- and ß2-subunits, containing nAchRs, underlies ADNFLE. The key pathogenetic 
mechanism underlying this inherited form of epilepsy is the “gain of function” of nAChRs 
containing the mutated α4 or ß2 subunits. Enhanced activity of the mutated nAChRs translates 
into abnormal cholinergic inputs to pyramidal cells or to GABAergic afferents in the frontal 
cortex (FC), such as enhanced nicotine-evoked IPSCs, which have been hypothesized to trigger 
network synchrony and ictal activity. Theoretically, blockade of nAChRs could provide a 
therapeutic approach to treat the disease. As described in Melis et al 2008, the suppression of 
neuronal nicotine's effect by PPAR-α involves a non-genomic mechanism, due to the rapid onset 
of agonist actions. Tyrosine phosphorylation of nAChRs modulates their functional properties in 
neurons; nAChRs are rapidly phosphorylated and dephosphorylated, and the dephosphorylated 
form of the receptor is more active. The balance between tyrosine kinases and phosphatases 
determines the net phosphorylation status of nAChRs, constituting an important regulatory 
mechanism for their activity at the plasma membrane, and offering an additional capacity for 
modulation of neuronal network functions. On these bases, we hypothesize that negative 
regulation of nAChRs by enhancing the activity of tyrosine kinase, should provide a mean 
to negatively regulate nAChRs in ADNFLE. The potent agonistic properties of PPAR-α open 
up a new role for these nuclear receptors far beyond their well-known effects on energy 
homeostasis and lipid metabolism.  
Based onour working hypothesis, we expect that either an enhancement of FAE levels (and 
therefore PPAR-α  activation), or direct PPAR-alfa stimulation, may be beneficial in the 
treatment of ADNFLE.  
PPAR-α agonists, such as fibrates, are already well-established therapeutic options for the 
treatment of hyperlipidemia. Recent studies have suggested that a long time used dietetic add-on 
treatment of epilepsy, represented by the ketogenic diet, share properties similar to those showed 
by fenfibrates, a class of drugs aimed at controlling and modulating lipid metabolism which has 
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also shown a antiepileptic effects on experimental models of epilepsy.  
The modulatory effects of such a class of drugs, spurs the rationale attempt to use, as add-on 
FENFIBRATE in NFLE treatment, given their modulation specifically upon the nicotinic 
mutated receptor. 
Ergo, we propose to explore whether the modulation of nAChRs by PPAR-alpha may be a 
feasible therapeutic strategy for ADNFLE\NFLE. 
To that, we performed electrophysiological and behavioral experiments first in a 
pharmacological epileptic animal model of the disease, than in a transgenic mouse model 
carrying a mutation homologous to that found in the human disease.  
We finally verified the clinical efficacy of an adjunctive therapy with fenofibrate in 
pharmacoresistant NFLE and ADNFLE patients.  
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INTRODUCTION 
 
 Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha 
and nicotine receptors: bases of the therapeutic target.  
 
 
 
 
 
 
 
 
Fatty acids have a different role in the brain as compared to their effects in peripheral tissues in 
terms of energy stores and production in situ. Although brain cells possess the enzyme 
machinery for fatty acid mitochondrial -oxidation, to generate ATP they mainly rely on glucose. 
Alternatively, under extreme physiological conditions they depend on ketone bodies [1]. In 
addition, because progressive brain damage is not a feature of mitochondrial -oxidation defects, 
mitochondrial fatty acid -oxidation most likely plays only aminor role in central nervous system 
(CNS) energy metabolism [2]. Peroxisomal oxidation upon nuclear receptor peroxisome 
proliferator-activated type alpha (PPAR-α) activation participates also in hydrogen peroxide 
production as well as in other facets of fatty acid metabolism. Conversely, peroxisomal -
Miriam  Melis , Marco  Pistis 
 Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: Therapeutic perspectives 
Pharmacological Research, Volume 86, 2014, 42 - 49 
http://dx.doi.org/10.1016/j.phrs.2014.03.009 
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oxidation dysfunction has been linked to neurodegeneration in human diseases [3, 4]. Therefore, 
brain fatty acid -oxidation (both mitochondrial and peroxisomal) has an important role in 
signaling pathways and catabolism of pro-inflammatory molecules such as eicosanoids. 
Palmitoylethanolamide (PEA) is a naturally occurring Nacylethanolamine (NAE), a saturated 
fatty acid (palmiticacid) derivative. NAEs are bioactive lipids, whose functions and properties 
were discovered first in 1957, when PEA (from soybeans, peanuts, and egg yolk) exerted 
antiinflammatory activity in guinea pigs [5]. High levels of PEA were also measured in 
mammalian tissues, especially in the brain [6]. 
 
The role of PEA, as well as of other NAEs, in the brain has been elucidated only recently, when 
the interest in lipid messengers was rekindled by the discovery that arachidonoylethanolamide 
(AEA, or anandamide), an NAE with an arachidonic acid (ARA) moiety, is an endogenous 
ligand to cannabinoid receptors [7]. NAEs, including AEA and the non-cannabinoid PEA and 
oleoylethanolamide (OEA), are lipid messengers produced “on demand”. In fact, they are not 
stored in vesicles, but released from membrane phospholipids (N-
acylphosphatidylethanolamines, NAPEs)[8] when cells are subjected to potentially harmful 
stimuli, such as membrane depolarization or increase of cytoplasmic Ca2+ levels. OEA and PEA 
lack binding affinity at cannabinoid receptors [9,10] and are considered being endogenous 
agonists at PPAR-α and other non-cannabinoid targets. The dopaminergic system consist of 
several pathways originating in the midbrain, particularly within the ventral tegmental area 
(VTA, A10) and the pars compacta of the substantia nigra (SNpc, A9), where dopamine 
synthesizing cells are located [11,12]. Dopamine cells project via their axons to their target 
regions in both cortical (medial prefrontal, cingulated, and entorhinal cortices) and other 
forebrain areas (striatum and nucleus accumbens, amygdala, olfactory tubercle) where dopamine 
is released [13,14,15]. 
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The different distribution of dopamine projections in these areas stemming from either the VTA 
or SNpc names the systems mesocorticolimbic and mesostriatal, respectively. Given that these 
systems are involved not only in motor control and movement disorders (e.g. Parkinson disease), 
but also in “higher” brain functions (e.g. emotional and cognitive tasks) and dysfunctions (e.g. 
schizophrenia, drug addiction) [16], their individual cellular properties [17], as well as their 
ability to change in response to altered functional demands are now considered extremely 
important. 
 
Despite the fact that evidence of the role of NAEs in the modulation of dopamine functions was 
shown [18-20], it is only with the discovery that these lipid molecules prevent nicotine-induced 
excitation of midbrain dopamine neurons via PPAR-α [21] that their role as fine regulators of the 
brain reward system emerged. 
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Hence, these findings opened a potential new avenue for the pharmacological treatment of 
nicotine addiction. Indeed, synthetic PPARα ligands, such as lipid lowering fibrates, prevent 
nicotine-induced excitation of dopamine neurons, and increased extracellular dopamine levels in 
the shell of the NAc [22], both of which represent a hallmark of its acute rewarding properties. 
PPARα activation can be achieved directly and indirectly. Hence, PPARα synthetic agonists 
such as fibrates are effective and safe marketed drugs for their lipid lowering pharmacological 
properties. In addition, PPARα activation can be attained by pharmacologically manipulating 
(i.e. enhancing) intracellular levels of its endogenous ligands. Hence, increased levels of FAEs in 
the midbrain can be obtained not only by preventing their degradation (e.g. URB597), but also 
by promoting their synthesis [23] and [24]. This is particularly relevant since increasing levels of 
PPARα endogenous ligands such as FAEs, but also free fatty acids, are able to influence 
neuronal activity of midbrain dopamine cells and to prevent their nicotine-induced excitation 
[25]. In the midbrain, FAE synthesis depends upon raises of intracellular Ca2+ and activation of 
α7-nAChRs [26]. Hence, either a hypercholinergic drive and direct activation of α7-nAChRs can 
powerfully increase OEA and PEA levels, and prevent nicotine-induced stimulating effects both 
in vitro and in in vivo [27]. In addition, although modifying brain fatty acid composition through 
changes in the diet is rather difficult, low concentrations of added fatty acids can affect FAE 
biosynthesis within the midbrain, an effect that most likely occurs through activation of PPARα 
[100]. Whether or not this effect can prevent nicotine actions on dopamine system function 
remains to be explored yet. Nonetheless, since PEA and OEA can modulate dopamine cell 
excitability [28] and [29], it is tempting to speculate that a nutritional approach might powerfully 
regulate their activity and metabolism via PPARα induction. 
 
 Importantly, OEA and PEA, by inducing mitochondrial enzymes and/or peroxisomal β-
oxidation [30], may also play a role in guaranteeing steady state levels of hydrogen peroxide 
required to regulate dopaminergic neuronal activity [31]. Accordingly, the cellular effects 
resulting from PPARα activation, such as decreased spontaneous activity of dopamine cells and 
blockade of nicotine-induced excitation of these neurons, are fully prevented when hydrogen 
peroxide half-life is reduced by raising the intracellular levels of catalase, and require 
β2*nAChRs [32]. Thus, FAEs as PPARα ligands act as intrinsic modulators of cholinergic 
transmission and alter dopamine cell excitability, contributing to acetylcholine effects on 
dopamine system. The findings that activation of α7-nAChRs activation on dopamine cells can 
selectively increase FAE levels to prevent their own aberrant excitation in response to high 
cholinergic drive suggested their involvement in other disorders characterized by an unbalance 
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between dopamine and acetylcholine systems [33]. Hence, since FAEs via PPARα seem to act as 
possible switches in the tonic/phasic transition regulated by β2*nAChRs, their role in mood 
control was suggested [34]. Accordingly, both PEA [115] and FAAH inhibitors display 
antidepressant-like activity in rodents [35-37]. 
 
Remarkably, FAEs may also play a role in the etiopathogenesis of schizophrenia. Accordingly, 
activation of either PPARα or α7-nAChRs has proven to be effective in preclinical models of 
schizophrenia [40-43], thus supporting this interplay in the pathophysiology of this disease [44-
46]. Noteworthy, the role played by FAEs in the pathophysiology of dopamine systems is further 
supported by a population study of the gene encoding FAAH [47-48] in which, by logical 
extension, the homozygosis for this FAAH missense polymorphism was also found associated 
with overweight and obesity [49]. Indeed, in the brain overlapping reward and reinforcement 
pathways likely modulate natural and artificial rewards, such as food and illicit drugs, 
respectively. Thus, the effects of the FAAH 385 A/A polymorphism could result in the 
amplification of those reward seeking behaviors such as the consumption of palatable and sweet 
foods that are usually associated with overweight and obesity [48]. 
 
Finally, yet importantly, altered functional properties of nAChRs are implicated in the 
pathogenesis of nocturnal frontal lobe epilepsy, linked to mutations of α4 or β2 subunits. 
Notably, PEA has proven to have antiepileptic effects in kindled rats, and displayed 
anticonvulsant activity in mice [54]. Accordingly, acute and chronic PPARα agonists are able to 
reduce nicotine-induced seizures, and to abolish nicotine-induced generation of ictal activity and 
synchrony in the frontal cortex. Remarkably, these latter observations were accompanied by an 
increased ratio of phosphorylated/dephosphorylated β2 subunits in the frontal cortex following 
acute PPARα ligand treatment, whereas the chronic regimen induced a threefold increase in 
OEA levels in the same brain region. Noteworthy, these findings may be extended to other 
models of epilepsy, since chronic fenofibrate was shown to be effective as anticonvulsant in 
pentylentetrazole-induced seizures and on latencies to the onset of status epilepticus induced by 
lithium–pilocarpine [49-55]. the role played by the FAEs, endogenous PPARα ligands, which act 
as endogenous modulators of cholinergic transmission, and alter intrinsic dopamine cell 
excitability, and dependent behavior. The reduced response to acetylcholine impinging on the 
same dopamine neuron releasing endogenous PPARα ligands might, thus, counterbalance the 
excessive cholinergic drive, and provide fine modulation of dopamine pathways at single-cell 
level, where phosphorylation of β2*nAChRs is the effector mechanism. Consequently, PPARα 
 13 
activation by FAEs may be suited to help resolve disruption of dynamic balance of dopamine-
acetylcholine systems, and prove beneficial in those disorders associated with dysfunction of 
such interplay.  
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Nocturnal Frontal Lobe Epilepsy: clinical and genetic features 
 
 Nocturnal frontal lobe epilepsy (NFLE) is caracterized by seizures that are almost exclusively 
sleep related. In the last few decades, the spread and refinement of video–polysomnographic (V-
PSG) technology has allowed NFLE to be fully defined and described, so that it is now 
considered a distinct epileptic syndrome (Provini et al. 1999). 
It is now recognized that NFLE is not a homogeneous disease as familial, idiopathic, sporadic, 
cryptogenetic, or symptomatic forms do exist. In addition, a genetic heterogeneity is also evident 
within the familial type. 
No epidemiologic data are available on NFLE prevalence. The frequency of pure sleep-related 
seizures, defined as “seizures occurring exclusively or predominantly (>90 %) from sleep” 
clusters around 12 % of people with epilepsy, the majority of patients being affected by focal 
epilepsy. NFLE is probably not rare, accounting for 13 % of polysomnographic recordings for 
nocturnal motor disorders in a retrospective study performed at a tertiary centre in Italy and for 
6.3 % of a large series of focal drug-resistant epileptic patients. Because many cases of NFLE 
are misdiagnosed as parasomnias, the clinical relevance of NFLE is underestimated, especially in 
children(Yaqub, Waheed, and Kabiraj 1997)(Fernández and Salas-Puig 2007). 
The genetic origin of the disease was firstly confirmed by a linkage study in Australian kindred. 
More specifically, a locus was identified at chromosome 20q13.2-q13.3 and two different 
mutations were detected in the gene coding the α4 subunit of the neuronal nicotinic acetylcholine 
receptor (nAChR) (CHRNA4). Both mutations were shown to have major effects on receptor 
function in vitro. With the identification of these mutations, subsequently confirmed in families 
of different origins, ADNFLE became the first epilepsy in which genetic bases were detected, 
and was quickly recognized as a genetically heterogeneous disorder showing mutations in the 
CHRNA4 gene and in the the β2 subunit of the nACh receptor (CHRNB2).  
 
For detailed description of genetic mutation see Nobili et al 2014  Curr Neurol Neurosci Rep. 
2014.  
 
Clinical Features and Sleep traits of NFLE 
 
ADNFLE and sporadic NFLE show similar clinical and electroencephalographic features. In the 
high majority of NFLE patients, seizures begin before the age of 20 years, with a peak during 
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childhood, although onset during adulthood has been also reported. Seizure frequency is usually 
high, and patients generally experience many seizures a night, although the frequency may 
diminish during adulthood. Of note, occasional seizures during wakefulness can occur (Oldani et 
al. 1998).  
The broad spectrum of clinical manifestations in NFLE includes motor phenomena of increasing 
complexity and duration ranging from major attacks (asymmetric tonic–dystonic posturing, 
hyperkinetic seizures, or prolonged epileptic nocturnal wandering), to paroxysmal arousals 
(frequent, abrupt, and brief arousals associated with stereotyped movements of the trunk and/or 
head elevation), and minor motor events, in the form of brief (2–4 s) stereotyped movements 
involving the limbs, the axial musculature, and/or the head (Terzaghi et al. 2008). 
Clinical manifestations of NFLE are strongly influenced by circadian sleep-wake alternation and 
by physiologic components of sleep structure. Regardless of their semiology, the majority of 
NFLE seizures arise during nonrapid eye movement (NREM) sleep and are followed by a 
sudden transition to a more superficial stage or a frank awakening. Furthermore, changes in 
autonomic cardiac control presumed to precede SO, represent part of the arousal response, which 
could be implicated in the occurrence of both seizure and arousal motor manifestations (Terzaghi 
et al. 2007). 
The epileptic fragmentation of the first part of the night can produce a significant sleep 
disruption with a consequent increase of wake after sleep onset (WASO) and rapid eye 
movement (REM) sleep latency but without alterations of slow-wave sleep (SWS), which even 
increases. Moreover, the temporal development of epileptic events across sleep period seems to 
be modulated by the homeostatic process of deep NREM sleep. Furthermore, changes in 
autonomic cardiac control associated with motor activity (phases of transitory activation) 
presumed to precede sleep onset, could represent part of the arousal response, which could be 
implicated in the occurrence of both seizure and arousal motor manifestations (Calandra et al. 
Sleep Med. 2012). 
The cyclic alternating pattern (CAP), the marker of unstable NREM sleep (Terzano et al. 2001)  
plays a primary role in the activation of epileptic events in NFLE patients (Parrino et al. 
2006)(Parrino, De Paolis, et al., 201)(Parrino, Ferri, et al. 2012). 
In NFLE patients, CAP is a powerful triggering condition for the occurrence of both ictal and 
interictal epileptic events that arise in concomitance with phase A. In turn epileptic 
manifestations act as a subcontinuous sleep disturbance that induces a significant increase of 
sleep instability. This enhancement of unstable NREM sleep together with the alterations of 
conventional sleep measures can define distinctive polysomnography (PSG) features in NFLE 
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patients and can be responsible for the poor sleep quality and the excessive daytime sleepiness, 
which has already been described in these patients(Parrino, De Paolis, et al. 2012). 
Because of the almost exclusive recurrence of seizures during sleep, NFLE patients often are 
scarcely aware of the presence, complexity, and frequency of attacks. Moreover, a reliable 
description of epileptic motor events occurring during the night often are difficult to collect from 
a witness or sleep partner, as observers may be absent, or if present, not fully awake or reliable. 
Lastly, MMEs often are difficult to be clearly qualified. 
For these reasons, nocturnal video-EEG features and PSG metrics can provide objective data of 
the effects of antiepileptic therapy, especially on minor seizures and sleep parameters.  
The discrepancy between an adequate subjective seizures outcome and PSG findings in treated 
NFLE subjects can open up the discussion to the identification of clinical and sleep measures, 
which can define a more objective response to treatment. The subjective effectiveness of 
antiepileptic treatment in NFLE subjects could be mostly related to the partial reduction of the 
longer and more complex nocturnal seizures that are more likely to be perceived. In contrast the 
persistence of residual objective PSG epileptic phenomena (both MAs and MMEs) and a high 
level of unstable NREM sleep indicate a partial resistance of both seizures and disturbed arousal 
system to the therapeutic action of the antiepileptic treatment (De Paolis et al. 2013). 
 
So far the principle target of antiepileptic treatment is to eliminate or decrease major epileptic 
events. However, despite the reduction of nocturnal seizures, the normalization of SE and 
WASO, and the high values of SWS in our NFLE subjects, daytime sleepiness is still present 
under drug treatment. The persistence of high values of CAP rate even under therapy could be a 
partial explanation of diurnal concerns. In this perspective, the goals of therapy in NFLE 
should include the treatment of structural sleep alterations. 
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The Role of the neuronal nicotinic acetylcholine receptors (nAChRs)* 
 
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand gated cationic channels that are 
composed of various combinations of five subunits arranged quasi-symmetrically around a 
central channel. They are encoded by nine α (α2-α10) and three β (β2-β4) subunit genes that 
show distinct patterns of expression both in neuronal and non-neuronal tissues. Each subunit is 
composed of three different parts, which include the extracellular, cytoplasmatic and 
transmembrane portions. The NH2-terminus is the largest extracellular domain, contains several 
glycosylation sites and, in α subunits, contributes the main components of the high-affinity 
ligand binding sites that are located at the interface between neighbouring subunits. This domain 
is important for receptor assembly and expresses the main immunogenic region. The four 
transmembrane regions (TM) probably have a mixed α-helical/non-helical secondary structure 
with their helical segments forming both an inner ring (TM2) that shapes the pore and an outer 
shell (TM3-TM4) that shields the inner ring from membrane lipids. The different subunits 
assemble to build two classes of nAChRs, the homomeric or heteromeric α-Bungarotoxin-
sensitive receptors that are composed solely from α subunits (α7-α10), and the heteromeric α-
Bungarotoxin-insensitive receptors that consist of various combinations of α and β subunits (α2-
α5, β2-β4).  
The mechanisms of nAChR activation, ion pore opening and closure and desensitisation are 
determined by highly conserved amino acid positions within the subunits. The function of the 
different neuronal nAChR subtypes depends on their subunit composition, their distribution 
within the brain as well as on their cellular location. Postsynaptic nAChRs often contribute to 
fast excitatory transmission, while preterminal and presynaptic nAChRs enhance 
neurotransmitter release (which, depending on the released transmitter, either increases 
inhibitory or exitcatory synaptic impulses), and nonsynaptic nAChRs are likely to modulate 
neuronal excitability.  
The nAChRs are involved in brain development and plasticity and participate in many different 
brain functions, including modulation of sensory inputs, locomotor activity, analgesia, attention, 
learning, memory and reward mechanisms. It is therefore not surprising that genetic variants in 
nAChR subunit genes were found to be associated with different common disorders and 
behaviours, including Alzheimer disease, schizophrenia and smoking related endophenotypes. 
However, the only monogenic disorder so far known to be caused by high penetrance mutations 
in neuronal nAChR is ADNFLE. 
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ADNFLE mutations in the nAChR subunits appear to modify the number and distribution of 
α4β2 nicotinic receptors in the living human brain. The distribution of α4β2 nicotinic receptors 
has been studied in eight ADNFLE patients carrying nicotinic receptor mutations (causative 
mutations: four 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. 
Miwa JM1, Freedman R, Lester HA. Neuron. 2011 Apr 14;70(1):20-33 
 
 
patients with α4-S280F (numbering according to reference sequence NP_000739.1) (mutation is 
also named S248F 2); two with α4-S284L (also named S252L 26); one with α4- T293I (also 
named T265I 28); and two with β2-V287L), by a PET-scan using [18F]-F-A-85380, a 
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radioligand with a high affinity for α4β2 nAChRs.  
This PET study demonstrated a regional nAChR density decrease in the prefrontal cortex, an 
observation consistent with partial epilepsy involving the frontal lobe. The increase of nAChR 
density in the mesencephalon suggests that these brain structures are involved in the 
pathophysiology of ADNFLE through the role of brainstem ascending cholinergic systems in 
arousal. Electrophysiological studies of the receptors carrying the different mutations identified a 
common alteration in their properties, corresponding to a gain of function. 
 
The theory of the  “Gain of function”. 
 
Mostly, seizures are characterized by short bursts of abnormal neuronal activity that, by their 
origin and spreading pattern in brain, determine the clinical phenotype of the epilepsy; arise from 
a state of hypersynchronisation that causes groups of neurons or whole neuronal networks to fire 
simultaneously. In ADNFLE these episodes are usually occur with NREM sleep phases  that can 
be subdivided into two main phases, one that consists of transient arousals and one that is 
characterised by tonic activities in the EEG. The association between the seizures and NREM 
phases suggests that sleep-controlling brain structures are involved in the pathogenesis of 
ADNFLE. One of the main regulators of sleep is the central cholinergic system that controls both 
the circadian clock and the sleep-wake cycle. Two major cholinergic cell groups are responsible 
for the cerebral activation that accompanies wakefulness and paradoxical sleep. One is located 
within the pontomesencephalic tegmentum that projects rostrally into the non-specific thalamo-
cortical relay system and the other is placed within the basal forebrain that receives input from 
the brainstem reticular formation and projects as the ventral, extrathalamic relay upon the 
cerebral cortex.  
Functional changes in nAChRs as those induced by ADNFLE mutations might affect these 
cholinergic projections and cause aberrations in sleep stages that, for unknown reasons, render 
certain neuronal networks more vulnerable for sudden bursts of hyperactivity during NREM 
sleep. An older hypothesis postulates that seizures are the result of reduced inhibition that causes 
an increase in excitatory neuronal activity. More recently it has been shown that the opposite 
mechanism is at least as plausible, and is the one most likely involved in seizures caused by 
nAChR subunits. The basic principle underlying this mechanism is an enhancement of neuronal 
synchrony by inhibition. It has been shown that pyramidal cells that are connected to the same 
GABAergic interneuron synchronise their firing when released from the interneuron’s inhibitory 
effect.  
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Interneurons innervating layer II/III pyramidal cells are known to carry α4β2 nAChRs. Triggered 
by the gain-of-function effect ADNFLE mutations exhibit on these receptors they could activate 
larger numbers of GABAergic interneurons that in turn could easily synchronise enough 
pyramidal cells to change local cortical activity from synchronisation to hypersynchronisation. 
Spreading of the hypersynchronisation into the motor control area would than be likely to cause 
the type of seizures typically associated with ADNFLE. Such a mechanism in which a gain-of-
function of certain nAChR subunits causes hypersynchronisation by increasing GABAergic 
inhibition is supported by animal models studies. GABA antagonists such as picrotoxin have 
shown to normalize the EEG and suppress spontaneous seizures in genetically altered pS280F-
KM mice.  
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*From:  
Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for 
Biotechnology Information (US); 2012. Steinlein OK, Kaneko S, Hirose S. Nicotinic acetylcholine receptor 
mutations 
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PPAR-ALPHA AGONISTS AS NOVEL ANTIEPILEPTIC DRUGS: 
PRECLINICAL FINDINGS. 
(Puligheddu et al. Plos One 2013) 
 
Abstract 
 
Nicotinic acetylcholine receptors (nAChRs) are involved in seizure mechanisms. Hence, 
nocturnal frontal lobe epilepsy was the first idiopathic epilepsy linked with specific mutations in 
α4 or β2 nAChR subunit genes. These mutations confer gain of function to nAChRs by increasing 
sensitivity toward acetylcholine. Consistently, nicotine elicits seizures through nAChRs and 
mimics the excessive nAChR activation observed in animal models of the disease. Treatments 
aimed at reducing nicotinic inputs are sought as therapies for epilepsies where these receptors 
contribute to neuronal excitation and synchronization. Previous studies demonstrated that 
peroxisome proliferator-activated receptors-α (PPARα), nuclear receptor transcription factors, 
suppress nicotine-induced behavioral and electrophysiological effects by modulating nAChRs 
containing β2 subunits. On these bases, we tested whether PPARα agonists were protective 
against nicotine-induced seizures. To this aim we utilized behavioral and 
electroencephalographic (EEG) experiments in C57BL/J6 mice and in vitro patch clamp 
recordings from mice and rats. Convulsive doses of nicotine evoked severe seizures and bursts of 
spike-waves discharges in ~100% of mice. A single dose of the synthetic PPARα agonist 
WY14643 (WY, 80 mg/kg, i.p.) or chronic administration of fenofibrate, clinically available for 
lipid metabolism disorders, in the diet (0.2%) for 14 days significantly reduced or abolished 
behavioral and EEG expressions of nicotine-induced seizures. Acute WY effects were reverted by 
the PPARα antagonist MK886 (3 mg/kg, i.p.). Since neocortical networks are crucial in the 
generation of ictal activity and synchrony, we performed patch clamp recordings of spontaneous 
inhibitory postsynaptic currents (sIPSCs) from frontal cortex layer II/III pyramidal neurons. We 
found that both acute and chronic treatment with PPARα agonists abolished nicotine-induced 
sIPSC increases. PPARα within the CNS are key regulators of neuronal activity through 
modulation of nAChRs. These effects might be therapeutically exploited for idiopathic or 
genetically determined forms of epilepsy where nAChRs play a major role. 
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Introduction 
 
Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits in laboratory animals 
dose-dependent effects that begin with hypermotility and culminate with clonic-tonic seizures 
and death at high doses [1]. Investigation on the mechanisms underlying nicotine-induced 
seizures might help to understand how nAChRs participate in the mechanisms of epilepsy. 
Interest for nAChR in several epileptic syndromes previously considered “idiopathic” was 
rekindled by the finding that altered functional properties of nAChR are implicated in the 
pathogenesis of nocturnal frontal lobe epilepsy (NFLE), and that seizures induced by nicotine in 
rodents model nAChR-related epilepsy. NFLE is linked with mutations of the α4 or β2 subunits 
[2], [3], [4], [5], [6], [7], the most abundantly expressed subunits in the CNS [8]. Though in 
human NFLE, or in genetically engineered mice that model the disease, functional properties of 
nAChRs are intimately altered, nicotine evokes seizures by over-activating a healthy system. 
However, several neurophysiological events ultimately leading to seizures may share common 
steps between these conditions. Indeed, the common trait in enhancing the epileptogenesis is the 
over-activation of cholinergic systems, either pharmacologically induced or mediated by the gain 
of function that mutated nAChRs exhibit toward their ligands [9]. These effects might be based 
on the extensive expression of nAChRs, particularly those containing the β2 subunit 
(β2*nAChRs) in thalamo-cortical, hippocampal and frontal regions [10]. Indeed, altered 
cholinergic activation of neocortical and/or thalamocortical networks plays a central role in the 
generation of both nicotine-induced and NFLE seizures, which originate in the frontal cortex 
(FCx) [11] and specifically affect GABAA-mediated inhibitory inputs to pyramidal neurons 
[12]. 
 
Based on this evidence, negative regulation of nAChRs might represent a potential therapeutic 
approach in nAChR-related forms of epilepsies. 
 
We previously discovered that nicotine-evoked excitation of dopamine neurons both in vivo and 
in vitro, as well as nicotine addictive properties in rats and monkeys, are suppressed by ligands 
to the peroxisome-proliferator-activated receptor-α (PPARα) [13], [14], [15], [16]. PPARα is one 
of three subtypes of the nuclear receptor PPAR family [17], [18], [19], expressed by neurons in 
many brain regions [20], [21], and activated by endogenous ligands, the N-acylethanolamines 
oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) [22], and by synthetic ligands 
such as hypolipidemic fibrates [16]. 
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Evidence points to a non-transcriptional interaction between PPARα and nAChR, via 
phosphorylation [13], [14], [23]. This mechanism might account for the blockade of neuronal 
and behavioral responses to nicotine [13], [15], [16]. 
 
Building upon these findings, we postulated that PPARα agonists might display anticonvulsant 
properties. Thus, we first investigated whether acutely or chronically administered PPARα 
ligands reduce the severity of nicotine-induced seizures. Next, we assessed whether these 
compounds regulate the phosphorylation status of the β subunit of the nAChR and abolish 
nicotine-induced enhancement of inhibitory currents on pyramidal neurons in layers II/III of the 
frontal cortex (FCx) in mice and rats. 
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Materials and Methods 
 
Animals 
For behavioral experiments, electroencephalographic (EEG) and patch-clamp recordings male 
C57BL/6J mice (Harlan, San Pietro al Natisone, Italy) (n = 80; weight: 25–30 g each) were used. 
For immuno-blotting experiments and patch-clamp recordings, we utilized male Sprague-
Dawley rats (250–300 g and 14–21 d, respectively, n = 30, Harlan, San Pietro al Natisone, Italy) 
Mice and rats were housed six per cage under a 12 h light/dark cycle (light on at 7:00 AM), in 
conditions of constant temperature (21±2°C) and humidity (60%), with food and water ad 
libitum. 
 
Ethics Statement 
Experiments were performed in strict accordance with the EEC Council Directive of 24 
November 1986 (86/609). All efforts were made to minimize pain and suffering and to reduce 
the number of animals used. The experimental protocols were also approved by the Animal 
Ethics Committee of the University of Cagliari. 
 
Treatments 
Animals were randomly assigned to the experimental groups undergoing behavioral seizure 
scoring or EEG recordings. In the first set of experiments a dose-response curve for nicotine (5, 
7, 10 mg/kg) was carried out. Each mouse received a single dose of nicotine. 
Subsequent acute experiments, aimed to assess the effect of the PPARα agonist WY14643 or the 
antagonist MK886, were carried out with the 10 mg/kg dose of nicotine. In these cases, mice 
received two injections, spaced by 10 min intervals, before the final nicotine administration after 
15 min: we first injected the antagonist MK886 (3.0 mg/kg, i.p.) or its vehicle followed by the 
administration of WY14643 (80 mg/kg, i.p.) or its vehicle. 
For chronic studies, one week after EEG electrode implants (see below) mice were divided into 
diet treatment groups: (i) a standard diet (control group, Harlan Teklad Global 2016); (ii) a 0.2% 
fenofibrate diet (Fenofibrate from Sigma-Aldrich+Harlan Teklad Global 2016). Mice were fed 
diets for 14 days. On the day of the experiment, mice received one injection [MK886 (3.0 mg/kg, 
i.p.)] or its vehicle before nicotine (10 mg/kg) administration after 15 min. 
 
Seizure Scoring 
Immediately after nicotine injection, mice were placed in a regular mouse cage with bedding, 
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and behavioral responses were recorded for 5 min. The symptoms were scored independently by 
two experimenters blind to the treatment on an arbitrary scale from 0 to 6 (modified from 
Franceschini et al., 2002) [24] as follows: 0, no visible effects; 1, locomotor effects including 
increased exploring activity and/or sedation; 2, tachypnea, tremors, back arching; 3, any 
combination of the symptoms in 1 and 2 plus rapid movements of the legs, wild running, or 
partial loss of righting reflex; 4, any combination of the previous symptoms plus complete loss 
of righting reflex, clonic seizures, 5, any combination of the preceding symptoms plus tonic 
seizures; 6, death, with or without hyperextension of the limbs along the axis of the body (soldier 
position). 
 
EEG Recordings 
Mice were anesthetized with Equithesin (5 ml/kg, i.p.) and placed in a stereotaxic apparatus 
(David Kopf, mod. 900). The skull was exposed and perforated, the holes aimed at the following 
positions: one located above the (either left or right) sensorimotor cortices (FPr and FPl), 
[coordinates from bregma (mm): anteroposterior +2, lateral 3, ventral to skull surface 1.5], two 
targeted to the dorsal hippocampus with bipolar leads glued together [coordinates from bregma 
(mm): anteroposterior +2, lateral 1 and 2, ventral 1.3 and 2] and one on the skull over the 
cerebellum as a reference [coordinates from bregma (mm): anteroposterior −5.9, lateral 1.5] [25]. 
A four-pin male socket was positioned into the holes, secured to the skull with epoxy resin and 
covered with acrylic cement to improve retention. 
One week following surgical preparation of the animals (or three to five weeks for chronic 
studies), experiments started according to the protocol described above, electrical potentials were 
acquired and the signals amplified, bandpass-filtered and recorded on a portable digital EEG 
polygraph (BQS 98 System Micromed). In addition, in view of the possibility that digital data 
generated by the above mentioned experimental settings may need unconventional processing, 
further home-made software analysis rewritten on a Matlab® platform was used (e.g. signal 
analysis with wavelets versus traditional fast Fourier transform (FFT) processing). 
Electrode impedance was maintained at <5 kΩ. The amplified signals, processed with a band-
pass filter (0.02 to 70 Hz), was stored on the hard disk at a sampling rate of 256/s. 
The behavior of the animals was video-recorded for the entire duration of the experiment. 
 
In vitro Electrophysiology 
 
The preparation of FCx slices and whole-cell patch clamp recordings from layer II/III pyramidal 
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neurons was as described previously [12]. Briefly, male mice (10–25 d, Harlan) and Sprague 
Dawley rats (14–21 d, Harlan) were anesthetized with halothane and killed. A block of tissue 
containing the FCx was sliced in the coronal plane (300 µm) with a vibratome (Leica, Nussloch, 
Germany) in ice-cold low Ca2+ artificial cerebrospinal fluid (ACSF) containing (in mM): 126 
NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose (pH 7.3–
7.4). Slices (two per animal) were transferred in a holding chamber and allowed to recover for at 
least 1 hr before being placed in the recording chamber and superfused with ACSF (32–34°C) 
saturated with 95%O2/5%CO2: 
FCx layer II/III pyramidal cells were identified visually with an upright microscope with infrared 
illumination, and whole-cell voltage-clamp recordings were made by using an Axopatch 200B 
amplifier (Molecular Devices, CA). All GABAA IPSC recordings were made with electrodes 
filled with an internal solution containing the following (mM): 140 cesium-methylsulfonate, 0.2 
EGTA, 5 NaCl, 10 HEPES, 2 Mg2ATP, 0.25 Mg2GTP, pH 7.2–7.4. Experiments were begun 
only after series resistance had stabilized (typically 15–40 MΩ). Series resistance and input 
resistance were monitored continuously on-line with a 4 mV depolarizing step (25 ms). Data 
were filtered at 2 KHz, digitized at 10 KHz, and collected on-line with acquisition software 
(Clampex 8.2, Molecular Devices, CA). Neurons were voltage-clamped at a membrane potential 
of 0 mV. All GABAA spontaneous IPSCs were recorded in presence of 2-amino-5-
phosphonopentanoic acid (AP5; 100 µM), 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline(CNQX; 
10 µM), to block N-methyl-D-aspartate- (NMDA), α-amino-3-hydroxy-5-methyl-isoxazoleprop
ionicacid- (AMPA) mediated synaptic currents, respectively. As already described [12], there 
was no effect of this solution on the holding current of the pyramidal cells. 
 
N-acylethanolamine Quantification 
Male C57BL/6J mice (Harlan, San Pietro al Natisone, Italy) were fed, as described above, with a 
standard diet or a 0.2% fenofibrate diet. After 14 days, mice were killed and brain rapidly 
removed. Frontal cortex slices were obtained and immediately frozen. Frozen slices were 
homogenized and extracted with chloroform/methanol/Tris-HCl 50 mM pH 7.5 (2:1:1, v/v) 
containing internal deuterated standards for PEA and OEA quantification by isotope dilution 
([2H]4 PEA, [2H]4 OEA; Cayman Chemicals, MI, USA). The lipid-containing organic phase 
was dried down, weighed and pre-purified by open bed chromatography on silica gel. Fractions 
were obtained by eluting the column with 90:10 (v/v) chloroform/methanol. PEA and OEA were 
quantified by liquid chromatography-atmospheric pressure chemical ionization-mass 
spectrometry (LC-APCI-MS) [(Agilent 1100 HPLC system (Agilent, Palo Alto, CA, USA) 
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equipped with MS Detector 6110 single quadruple)], and using selected ion monitoring at M +1 
values for the four compounds and their deuterated homologues, as previously described [26], 
[27]. 
 
 
 
Phosphorylation of nAChRs 
Phosphorylation of the β2*-nAChRs by the PPARα agonist was assessed ex vivo by 
immunoblotting in rat brain homogenates. Rats (250–300 g) were treated with the PPARα 
agonist WY14643 (40 mg/kg, i.p.) or vehicle and killed after 15 min. Brains were rapidly 
removed and the FCx was immediately frozen in liquid nitrogen. The tissue was then sonicated 
in cell lysis buffer (50 mM TRIS, pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM 
sodium orthovanadate, 1% Triton X-100, 0.02% NaN3) containing1 mM phenylmethylsulfonyl 
fluoride and protease inhibitor cocktail. Protein concentrations of the lysates were measured by 
the Bio-Rad Dc Protein Assay. 
β2 subunit protein was immunoprecipitated from whole-cell lysates using a rabbit polyclonal 
antibody raised against a recombinant protein corresponding to amino acids 342–433 of the 
human β2 subunit (sc-11372, Santa Cruz Biotechnology). Antibodies were coupled to protein A 
Dynabeads (Invitrogen) using 5 µg anti-β2 antibody by rotating the mixture for 10 min at room 
temperature. Beads were washed twice in PBS and then the antibody-conjugated beads were 
incubated with 500 µg of protein lysate for 10 min at 4°C, followed by 3 washing steps in PBS 
supplemented with 0.1% Tween 20 (Sigma-Aldrich). Bound protein was eluted with 4× XT 
Sample buffer (Bio-Rad) and Reducing agent (Bio-Rad). 
The immuno-precipitates were separated on an XT Criterion 10% gel (Bio-Rad, Copenhagen, 
Denmark) with 1× XT MOPS running buffer (Bio-Rad) for 1 hour at 175 V (constant) and 
subsequently electro-transferred to a nitrocellulose membrane at 400 mA (constant) for 1 hour. 
The membranes were incubated with 4G10 anti-phosphotyrosine (PY) antibodies (Upstate 
Biotechnology). 
Chemiluminescence was detected and quantified with the Versa Doc 1000 Imaging System (Bio- 
Rad Laboratories, Hercules, CA, USA). Samples from control and treated rats were run on the 
same immunoblots and then analyzed together. Values obtained from treated rats were calculated 
as percentage of control values. 
 
Drugs 
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Nicotine [(−)-nicotine hydrogen tartrate)] and fenofibrate were purchased from Sigma (Italy). 
Nicotine was dissolved in 0.9% NaCl solution and the pH was adjusted to 7.0 with 0.1 M NaOH. 
Concentrations were adjusted for the mouse to receive 10 µl/g of nicotine solution. WY14643 
and MK886 were purchased from Tocris. WY14643 and MK886 were dissolved in a solution 
containing 10% Tween80, 20% dimethyl sulfoxide (DMSO) and 70% distilled water. All drugs 
for patch-clamp experiments were dissolved in DMSO as stock solutions and then diluted to the 
final volume in ACSF (final concentration <0.01%). 
 
Statistical Analysis 
 
Seizure scores (expressed as mean ±95% confidence interval, C.I.) were analyzed by utilizing 
Kruskal-Wallis test for non-parametric data, and Dunn’s test as a post-hoc. 
Electrophysiological experiments were sampled on line and off line with data analysis 
electrophysiology software by computers connected to specific interface. Drug-induced changes 
in sIPSCs were calculated by averaging the effects following drug administration and normalized 
to the pre-drug baseline. 
Data were analyzed utilizing parametric one-way ANOVA or Student’s t-test, when they had 
equal variance and were normally distributed; nonparametric t-test was utilized in all other 
circumstances. Post hoc multiple comparisons were made using the Dunnett’s or Newman-
Keuls’test when appropriate. Western blot data were analyzed using Student’s t-test. 
Contingency tables were analyzed using Fisher’s exact test. Alpha was set at P<0.05. All 
analyses were performed using the software Statistica 6 (StatSoft inc. Tulsa, OK, USA). 
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Results 
 
Measurement of Nicotine-induced Seizures 
 
Nicotine was subcutaneously administered at the doses of 5 (n = 4), 7 (n = 5), and 10 mg/kg (n = 
18) in mice and its effects were observed during 5 min after injection by two observers blind to 
the treatment. Data for behavioral observations were also obtained from mice carrying electrodes 
for EEG recordings, and were pooled with those obtained from non-implanted animals. 
After a first exploratory phase, mice displayed impaired locomotor activity with shakes. A few 
seconds later they developed strong tachypnea with tremors, back arching, and partial loss of 
righting reflex. At higher doses, the previous symptoms were followed by increased locomotor 
activity, with rapid movements of the legs and wild running. Clonic and tonic seizures occurred 
after complete loss of righting reflex. Fig. 1A shows that nicotine elicited seizures with dose-
dependent severity (r2 = 0.76, P<0.001). The calculated ED50 for nicotine was 5.08±0.07 mg/kg, 
similar to that already reported in the literature for the same mouse strain [24]. Only the dose of 
10 mg/kg was able to induce severe symptoms, which scored higher than 3. In this case, the 
number of animals which scored 4 or 5 was 15 out of 18 (83%) and, therefore, we chose this 
dose for the subsequent experiments. 
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Figure 1. The PPARα agonist WY14643 reduces nicotine-induced seizures. 
(A) Graph displaying the dose-dependency of the severity of nicotine-induced seizures in 
C57BL/6 mice. Nicotine was administered subcutaneously at 5, 7 and 10 mg/kg (n = 4, n = 5, n 
= 18, respectively). (B) Schematic representation of the experimental protocol of experiments in 
(C) and (D). (C) The PPARα agonist WY14643 (WY, 80 mg/kg, i.p., n = 23) reduced the 
severity of nicotine-induced seizures (nicotine dose: 10 mg/kg, s.c) (*P<0.05 vs. vehicle, 
Dunn’s-test). This effect was abolished by the selective PPARα antagonist MK886 (MK, 3 
mg/kg, i.p.). (n = 16, # P<0.001 vs. WY, Dunn’s-test). (D) This graph shows that the percentage 
of mice undergoing severe nicotine-induced seizures (indexed by scores >3) is significantly 
attenuated after WY14643 pretreatment (*P<0.05 vs. vehicle, Fisher’s test). MK886 reversed 
this effect (P>0.05 vs. vehicle, Fisher’s test). Data are expressed as mean±95% C.I. 
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The PPARα agonist WY14643 Acutely Reduces the Severity of Nicotine-induced Seizures 
 
To test the effect of the PPARα agonist WY14643 (WY, 80 mg/kg, i.p.) and the antagonist 
MK886 (MK, 3 mg/kg, i.p.) on nicotine-induced seizures, mice were randomly assigned to three 
groups: i) the vehicle-vehicle-nicotine (VEH group), ii) the vehicle-WY-nicotine group (WY 
group), and iii) the MK886-WY-nicotine group (MK-WY group). Each animal received the three 
injections spaced 10 and 15 min (Fig. 1B). 
 
When scores were evaluated, non-parametric ANOVA yielded a highly significant difference 
among groups (P<0.0001, Kruskal-Wallis test) (Fig. 1C). Post-hoc analysis revealed that mice 
pre-treated with the PPARα agonist WY14643 were significantly protected against nicotine-
induced seizures when compared with vehicle pre-treated animals. The difference in the average 
score was statistically significant (VEH mice: 3.8±0.4, n = 18; WY mice: 2.9±0.5, n = 24; P = 
0.019, Dunn’s test) (Fig. 1C). Additionally, WY mice which obtained a score of 4 or 5 were 46% 
of all treated mice (11 out of 24). The difference was statistically significant when compared 
with the VEH-group (15/18, 83%) (P<0.05, Fisher’s test, Fig. 1D). The protective effect of WY 
was reverted by the PPARα antagonist MK. Hence, post-hoc analysis indicated that in the MK-
WY-group the severity of nicotine-induced seizures was restored, since the average score was 
significantly higher than that assigned to the WY mice (4.4±0.5, n = 16, P = 0.001, Dunn’s test, 
Fig. 1C), but not different from that of VEH-mice (P>0.05, Dunn’s test) (Fig. 1C). Consistently, 
MK-WY mice receiving a score of 4 or 5 were 15 out of 16 (94%) (P = 0.6 vs. VEH mice) (Fig. 
1D). 
 
In vivo electrophysiological recordings revealed that high doses of nicotine elicited seizures that 
originate in the hippocampus [28] and in the thalamo-cortical pathways [11]. These neural 
circuits may also be involved in NFLE (for review, see [29]). For this reason, one EEG electrode 
was placed in the sensorimotor cortex and two in the dorsal hippocampus. Of the two electrodes 
positioned in the hippocampus the one with the best signal was chosen. 
 
As depicted in Fig. 2, nicotine-induced (10 mg/kg, s.c.) convulsive activity was paralleled by a 
synchronous spiking discharge pattern both in the hippocampus and in the cortex in 7 out of 7 
(100%) treated mice (Fig. 2A, B). Spiking activity had an onset of 130±7 s after nicotine 
injection and a duration of 52±10 s (n = 7). No spike/wave discharge events were recorded in 
vehicle treated mice (Fig. 2 A, B). 
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 Figure 2. The PPARα agonist WY14643 suppresses nicotine-induced spike-wave activity. 
(A) Representative traces of EEG recordings from hippocampal (Hip) and sensorimotor cortical (Ctx) electrodes 
chronically implanted in mice. Following the administration of vehicle (VEH) and 10 mg/kg nicotine, bursts of 
synchronous spike-wave (SW) activity with high-amplitude and low-frequency (most in the delta rhythm range) 
were recorded. This activity was suppressed when animals were pretreated with the PPARα agonist WY14643 (WY, 
80 mg/kg), which per se did not change baseline EEG activity. The PPARα antagonist MK886 (MK, 3 mg/kg, i.p.) 
restored nicotine-induced SW discharges. (B) The graph shows the percentage of mice presenting SW discharges 
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following the three treatment protocols. Vehicles treated mice did show SW activity, whereas 100% of nicotine 
treated mice displayed bursts of SW activity. The effects of nicotine were blocked in the majority of WY treated 
mice, since SW burst were recorded only in 33% of treated animals (**P<0.01 vs. vehicle, Fisher’s test). 
Conversely, when MK was administered 15 before WY nicotine-induced SW activity was recorded in 78% of 
MK+WY treated mice (#P<0.05 vs. WY, Fisher’s test). 
Pretreatment with WY significantly attenuated the effects of nicotine, since only 3 out of 9 
(33.3%) mice displayed spiking activity when compared with vehicle-treated mice (P<0.05, 
Fisher’s test, Fig. 2B). WY pretreatment, however, did not change either the onset or the 
duration of spike-wave activity in those animals not responding to the treatment (114±66 s and 
32±18 s, respectively, n = 3). Consistent with behavioral experiments, MK prevented WY-
induced protection from seizures, since nicotine’s effect was restored in 7 out of 9 mice (77.8%) 
(Fig. 2A, B). 
 
Chronic Administration of the Clinically Available PPARα agonist Fenofibrate Attenuates the 
Severity of Nicotine-induced Seizures. 
The results of the previous experiments prompted us to assess the efficacy of the clinically 
available PPARα agonist fenofibrate. Fenofibrate does not cross the blood-brain barrier rapidly 
enough to allow acute studies in vivo; therefore, we chronically treated the animals with a diet 
containing 0.2% w/w fenofibrate [30]. Mice were randomly divided into three groups: (i) 
fenofibrate diet (FBR), (ii) control diet (CTRL) and (iii) fenofibrate washout diet (FBR-WO). 
The fenofibrate containing diet was administered ad libitum for 14 days. FBR mice consumed a 
daily average of 3.6±0.1 g of food pellets, which approximately corresponds to 28–30 mg/kg 
fenofibrate per day. FBR mice were divided in two additional groups at the end of the treatment: 
one group received the PPARα antagonist MK886 15 min before the nicotine challenge, and the 
other received its vehicle. CTRL mice were fed with the control diet, identical and equicaloric 
but without fenofibrate. FBR-WO mice were fed for 14 days with a fenofibrate-containing diet, 
as FBR mice, and then fed with a control diet for additional 14 days to assess the effect of 
fenofibrate washout. In each animal EEG electrodes were implanted 7 days before the beginning 
of the treatments and nicotine was tested on the 15th day from the beginning of treatment (for 
FBR and CTRL mice) or on the 30th day (for FBR-WO mice). 
When nicotine-induced seizures were scored, non-parametric ANOVA yielded a highly 
significant difference among groups (P<0.0001, Kruskal-Wallis test) (Fig. 3A). Post-hoc analysis 
revealed that FBR mice were significantly protected against nicotine-induced seizures when 
compared with CTRL animals. The difference in the average score was statistically significant 
(CTRL mice: 3.4±0.7, n = 14; FBR mice: 2.1±0.3, n = 8; P<0.001, Dunn’s test) (Fig. 3A). 
Additionally, none among the FBR mice obtained a score of 4 or 5 (0 out of 8) (Fig. 3 B). The 
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difference was statistically significant when compared with the CTRL group (11/14, 78%) 
(P<0.001, Fisher’s test, Fig. 3B). The protective effect of the fenofibrate diet was not reverted by 
the PPARα antagonist MK. Hence, post-hoc analysis indicated that in the MK-treated FBR mice 
the severity of nicotine-induced seizures was not restored, since the average score was 
significantly lower than that assigned to CTRL mice (2.4±0.4, n = 8, P<0.001, Dunn’s test, Fig. 
3A), but not different from that of FBR-mice (P>0.05, Dunn’s test) (Fig. 3A). Consistently, no 
MK-treated FBR mice received a score of 4 or 5 (Fig 
 
 
 
 
Figure 3. The clinically used PPARα agonist fenofibrate chronically administered with food reduces nicotine-
induced seizures and spike-wave activity, and increases the OEA levels in the frontal cortex. 
(A) Graph displaying that fenofibrate (n = 8, FBR, 0.3% w/w in the diet for 14 days) reduced the severity of 
nicotine-induced seizures (nicotine dose: 10 mg/kg, s.c) (***P<0.001 vs. control diet, CTRL DIET, Dunn’s-test). 
This effect was not abolished by the selective PPARα antagonist MK886 (FBR+MK, 3 mg/kg, i.p.) (n = 8, **P<0.01 
vs. CTRL DIET, Dunn’s-test) but by withdrawal of fenofibrate treatment for 14 days (FBR WASH-OUT, n = 8, # 
P<0.05 vs. FBR and P>0.05 vs. CTRL DIET, Dunn’s test). (B) This graph shows that the percentage of mice 
undergoing severe nicotine-induced seizures (indexed by scores >3) is significantly attenuated after chronic 
fenofibrate treatment (***P<0.001 vs. control diet, Fisher’s test) and restored after fenofibrate withdrawal for 14 
days (#P>0.05 vs. control diet). MK886 did not reverse this effect (***P<0.001 vs. control diet, Fisher’s test). (C) 
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Chronic activation of PPARα by fenofibrate changes oleoylethanolamide (OEA), but not palmitoylethanolamide, 
levels within frontal cortex. Concentrations of these endogenous PPARα ligands are expresses as pmol per gram of 
tissue. Error bars depict S.E.M. (*P<0.05, Student’s t-test). (D) Representative traces of EEG recordings from 
hippocampal (Hip) and sensorimotor cortical (Ctx) electrodes chronically implanted in mice. In mice fed with 
control diet 10 mg/kg nicotine elicits bursts of synchronous spike-wave (SW) activity with high-amplitude and low-
frequency (most in the delta rhythm range). This activity was suppressed in animals fed with fenofibrate in food 
pellets. (E) The graph shows the percentage of mice presenting SW discharges following the four treatment 
protocols. 86% of control diet fed mice (6 out of 7) did show nicotine-induced SW activity. The effects of nicotine 
were fully blocked in all fenofibrate treated mice, since SW burst were recorded only in none of treated animals 
(***P<0.01 vs. control diet, Fisher’s test). MK, administered 15 before nicotine, did not restore nicotine-induced 
SW activity (***P<0.001 vs. control diet, Fisher’s test), whereas fenofibrate washout did (#P>0.05 vs. control diet, 
Fisher’s test). Data are expressed as mean±95% C.I. 
The lack of effect by MK could be explained by the fact that PPARα activation induces 
mitochondrial activity, peroxisomal β-oxidation and the biosynthesis of endogenous PPARα 
ligands, the N-acylethanolamines OEA and PEA. These combined effects might trigger a feed-
forward mechanism to further sustain PPARα activity [31]. To test this hypothesis we measured 
the levels of OEA and PEA in the FCx from FBR and CTRL mice. As predicted, in FBR mice 
OEA levels were significantly increased in the FCx when compared to CTRL mice (729.5±73.4 
pm/g vs. 484.3±38.4 pm/g; n = 5; P<0.05, Student’s t-test) (Fig. 3C). No changes of PEA levels 
were detected (FBR: 221.7±23.0 pm/g; CTRL: 245.6±18.4 pm/g; n = 5; P = 0.44 Student’s t-test) 
(Fig. 3C). 
Fenofibrate washout for 14 days abolished the protective effects of the drug, since in FBR-WO 
mice the severity of nicotine-induced seizures was restored (Fig. 3A). FBR-WO mice received a 
score of 3.5±0.6 (n = 8), significantly higher that FBR mice (P<0.05, Dunn’s test) but not 
dissimilar from CTRL mice (P>0.05, Dunn’s test) (Fig. 3A). 
EEG recordings revealed that nicotine-induced (10 mg/kg, s.c.) convulsive activity was 
paralleled by a synchronous spiking discharge pattern in both the hippocampus and the cortex in 
6 out of 7 (86%) CTRL mice (Fig. 3D, E). Spiking activity had an onset of 148±8 s after nicotine 
injection and a duration of 53±9 s (n = 6). 
The effect of nicotine was significantly attenuated in FBR mice, since only 2 out of 8 (25%) 
mice displayed spiking activity, when compared with CTRL mice (P<0.05, Fisher’s test, Fig. 
3E). In FBR mice, however, neither the onset nor the duration of spike-wave activity changed in 
those animals not responding to the treatment (179.5±25 s and 27±2 s, respectively, n = 2). 
The effects of nicotine were restored in FBR-WO mice: spiking activity was indeed present in 5 
out of 8 mice (P>0.05 vs. CTRL mice, Fisher’s test) (Fig. 3E). Consistent with behavioral 
experiments, MK did not block FBR-induced protection from seizures, since nicotine’s spike-
wave activity was assessed in 2 out of 8 mice (25%) (Fig. 3E). 
 
PPARα Agonists Suppress Nicotine-induced sIPSCs in Layer II–III Pyramidal Neurons in 
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the Mouse and Rat Frontal Cortex 
Nicotine-induced seizures, as well as those spontaneously occurring in transgenic mice carrying 
the NFLE mutations, might be primarily generated within FCx circuits [12], [29]. Since 
excitatory transmission on FCx pyramidal neurons is not affected by NFLE mutations or by 
nicotine [12], we carried out whole-cell recordings of spontaneous inhibitory postsynaptic 
currents (sIPSCs) from layer II/III pyramidal cells of mouse and rat coronal slices. 
 
Under voltage-clamp mode (Vholding = 0 mV to isolate sIPSCs [12]), nicotine (5 µM, 30 s) 
significantly increased both frequency and amplitude of sIPSCs in mouse pyramidal cells. sISPC 
frequency was enhanced to 133.2±2.9% of baseline (P<0.0001, n = 23, paired t-test), the 
amplitude to 116.5±7.5% of baseline (P<0.05, n = 23, paired t-test) (Fig. 4, Table 1). In marked 
contrast, pretreatment with the PPARα agonists WY (1 µM, 5 min) and fenofibrate (10 µM, 5 
min) dramatically blunted the effect of nicotine on sIPSCs. During nicotine application in the 
presence of WY, sIPSC frequency was 91.8±10.2% of baseline and amplitude was 91.8±4.7% of 
control values (for both parameters, P>0.05 vs. baseline, n = 7, paired t-test) (Fig. 4A, Table 1). 
Consistently, the structurally different PPARα agonist fenofibrate also suppressed nicotine-
induced increase of sIPSC frequency and amplitude (for both parameters, P>0.05 vs. baseline, n 
= 6, paired t-test) (Fig. 4B, Table 1). 
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Figure 4. The PPARα agonists WY14643 and 
fenofibrate suppress nicotine-induced increase of 
spontaneous inhibitory postsynaptic currents (sIPSC) 
in frontal cortex (FCx) pyramidal neurons. 
The graphs illustrate that in mouse FCx slices, nicotine 
(5 µM perfused at arrows for 30 s) increases sIPSCs 
frequency in layer II/III pyramidal neurons. Acutely, the 
PPARα agonists WY14643 (1 µM, WY) (A), and 
fenofibrate (10 µM) (B) fully suppressed nicotine-
induced increase in sIPSC frequency. Similarly, chronic 
fenofibrate (0.2% w/w for 14 days in food) fully 
suppressed nicotine-induced increase in sIPSC frequency 
(C). The gray box represents the time of PPARα agonist 
(+/− antagonist) perfusion. The PPARα antagonist 
MK886 (0.3 µM) (open symbols) blocked the effects of 
acute WY (A) and fenofibrate (B), but not the one of 
chronic fenofibrate (C), and restored nicotine-induced 
increase in sIPSCs. Representative recordings of the 
effect of nicotine, and of PPARα agonists and antagonist, 
on spontaneous IPSCs from pyrami 
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The effects of both PPARα agonists were blocked by the synthetic PPARα antagonist MK. In the presence of MK 
(0.3 µM, 5 min) and either PPARα agonist, nicotine effects on sIPSCs frequency and amplitude were fully restored. 
Hence, in slices perfused with WY+MK or fenofibrate+MK, nicotine induced an increase in sIPSC frequency to 
141.7±19.3% and to 172.5±20.9% of baseline, respectively (P>0.05vs. nicotine alone, n = 6–7, paired t-test; Table 
1,Fig. 4A,B). Table 1 shows that sIPSC amplitude in the presence of nicotine alone was not significantly different 
from the amplitude in the presence of nicotine+WY+MK or nicotine+fenofibrate+MK(P>0.05, n = 6, paired t-test). 
To assess whether suppression of nicotine effects by acute PPARα agonists was species-specific we replicated the 
experiments described above in Sprague Dawley rats. The results (Supporting Results S1) confirmed that both WY 
and fenofibrate abolished nicotine-induced effects in both species (Table 1; Figure S1). 
Experiments with mice chronically fed with fenofibrate (0.2% w/w for 14 days) confirmed that this drug abolishes 
nicotine-induced increases in sIPSC frequency in FCx pyramidal neurons. Hence, nicotine-induced increase in 
sIPCS frequency was 132.2±4.6% of baseline (n = 6) in CTRL mice vs. 99.7±5.6% of baseline (n = 6) in FBR mice 
(P<0.05, Student’s t-test) (Fig. 4C). Consistent with behavioral experiments, MK was unable to revert the effect of 
fenofibrate, since in FBR mice MK did not restore the effects of nicotine (sIPSC frequency in control animals was 
187.5±20.9% vs. 80.7±17.6% in FBR mice). 
The PPARα Agonist Enhances Phosphorylation of the β2 Subunit of nAChRs 
Consistent with our previous reports [13], [14], these findings led us to hypothesize that PPARα might regulate the 
balance between phosphorylated and dephosphorylated β2*nAChRs. To test this hypothesis, we analyzed 
phosphorylation of β2 subunits with Western blot after in vivoexposure to the synthetic PPARα agonist WY. Rats 
were administered WY (40 mg/kg, i.p.) and after 15 min, brain were rapidly removed and the FCx were dissected. 
As expected, in FCx total homogenates an increased immunoreactivity for phosphorylated β2 subunits was observed 
in WY-treated animals (125.0±7.9% of controls, n = 7, p<0.01, Student’s t-test) (Fig. 5). 
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The PPARα agonist WY14643 
enhances phosphorylation of 
β2 subunits of the nicotinic 
acetylcholine receptors. 
 
 
 
                 
…………………………………………………………………………….. 
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Discussion 
 
Our study shows that acute and chronic PPARα agonists, including the clinically available 
fenofibrate, reduce nicotine-induced behavioral and EEG seizure expression and abolish 
nicotine-induced enhancement of sIPSCs in FCx pyramidal neurons. 
 
We presume, based on the present results and previous extensive work by our group, that the 
mechanism whereby PPARα exerts these effects involves phosphorylation of specific nAChR 
subunits [13], [14], [22], [23]. Indeed, nAChR channel properties depend on its tyrosine 
phosphorylation status, being the result of a balance between tyrosine kinases and phosphatases 
[32], which negatively or positively modulates nAChR-mediated currents, respectively, and 
controls the number of functional surface receptors [33]. 
 
We specifically measured the ratio of phosphorylated/dephosphorylated β2 subunits, which is 
increased in the FCx by acute PPARα ligand treatment, but it is difficult to quantify this effect in 
subunit combinations less abundantly expressed in the CNS. Therefore, we cannot exclude that 
subunits other than the β2 might also be targeted by PPARα. However, it must be pointed out 
that β2*nAChRs play a major role, yet not exclusive, in nicotine-induced seizures [10], [34]. In 
fact, the α4β2 subunit combination is the most abundantly expressed in the whole brain and 
particularly in regions relevant to ictogenesis, such as thalamo-cortical circuits and FCx (see [12] 
and references therein). Furthermore, it was shown by Klaassen et al. [12] that nicotine-induced 
sIPSC in layer II/III of the FCx are mediated by α4β2 nAChRs, as they are insensitive to the α7-
selective blocker methyllycaconitine but fully blocked by the α4β2-selective antagonist dihydro-
β-erythroidine. However, it must be pointed out that other nAChR subunits are implicated in 
nicotine-evoked seizures. In particular, their severity is reduced in mice lacking α3, α5, and β4 
[35], [36], but not α7 [24]. The role of α7, however, is still controversial, since pharmacological 
experiments with selective α7 agonists and antagonists yielded contradictory results [10], [34]. 
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Irrespectively of the subunits involved other than β2, the PPARα agonists reduced both the 
severity of nicotine-induced effects and the number of animals undergoing severe symptoms. 
These behavioral effects were paralleled by a significant decrease in the number of mice that 
showed bursts of spike-wave discharges. The pharmacological specificity was confirmed by the 
finding that pre-treatment with the PPARα antagonist prevented the protection exerted by the 
agonist, with the exception of chronic fenofibrate treatments. The latter finding might be 
explained with the finding that PPARα activation induces fatty acid metabolism [31] and NAE 
biosynthesis with increased production of OEA. Notably, OEA would further sustain PPARα 
activation by triggering a feed-forward mechanism difficult to be antagonized by a single 
administration of the PPARα antagonist MK. A second possible explanation is that changes 
induced by this treatment regimen, possibly on function, number and phosphorylation status of 
nAChRs, are not promptly reversed by an acute treatment with the PPARα antagonist. Indeed, a 
reversal of fenofibrate-induced protection is observed following a 14-days washout of the drug, 
achieved by replacing fenofibrate-containing food pellets with control food. 
 
The present data, while confirming the relationship between nAChRs and epileptogenesis, give 
support to the role played by nuclear receptors PPARα in the modulation of nAChR function in 
the CNS. Hence, in our previous studies, we demonstrated that both endogenous and synthetic 
PPARα agonists suppressed nicotine-induced electrophysiological effects on dopamine neurons 
and prevented behavioral effects of nicotine predictive of its addicting properties by regulating 
β2* nAChRs specifically [13], [14], [15], [16]. Here we extend those results to the seizure-
inducing action of nicotine. 
 
Nuclear and cytoplasmic immunostaining for PPARα is present in neurons distributed in all 
layers of the FCx [20], [21], whereas cholinergic afferents, arising principally from the basal 
forebrain, innervate neurons in all layers of the rodent FCx [37]. Several subtypes of GABA 
cortical interneurons express functional α4β2* nAChRs [38], [39] and have been involved in 
nicotine-induced seizures [10], [12], [34], [38] since they innervate adjacent pyramidal cells. 
Consistently, we show that nicotine induced an increase in the frequency of GABAA-mediated 
sIPSCs, possibly by depolarizing presynaptic GABAergic terminals impinging on pyramidal 
neurons. According to behavioral observations, these effects were suppressed by PPARα 
agonists, suggesting that PPARα regulate the functions of nAChRs in cortical interneurons, 
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similarly to dopamine neurons. 
 
Notably, the relevance of our results might extend beyond nicotine-induced seizures or NFLE, 
since chronic fenofibrate was effective in rats as anticonvulsant in pentylentetrazole-induced 
seizures and on latencies to the onset of status epilepticus induced by lithium–pilocarpine [30]. 
Additionally, recent studies demonstrated that the antiepileptic drugs carbamazepine and 
lamotrigine, which are employed effectively also in NFLE patients, negatively modulate the 
activity of α4β2 nAChRs [40], [41]. This effect might contribute to their mechanisms of action 
since these receptors control neuronal excitability and both glutamate and GABA release in the 
hippocampus and the thalamo-cortical system [42], [43], [44], [45], [46]. 
 
In conclusion, we provided evidence that PPARα within the CNS might be a key regulator of 
neuronal activity by the modulation of functional properties of nAChRs. These effects might be 
therapeutically exploited not only when nicotine addiction is concerned [15], but also for 
idiopathic or genetically determined forms of epilepsy where nAChRs play a major role. 
  
 50 
 
 
 
 
 
The PPARα agonists WY14643 
and fenofibrate suppress nicotine-
induced increase of spontaneous 
inhibitory postsynaptic currents 
(sIPSC) in rat frontal cortex (FCx) 
pyramidal neurons. The graphs 
illustrate that in rat FCx slices, 
nicotine (5 µM perfused at arrows 
for 30 s) increases sIPSCs 
frequency in layer II/III pyramidal 
neurons. The PPARα agonists 
WY14643 (1 µM, WY) (A) and 
fenofibrate (10 µM) (B) (n = 6–7; 
closed symbols) fully suppressed 
nicotine-induced increase in 
sIPSC frequency. The gray box 
represents the time of PPARα 
agonist (+/− antagonist) perfusion. 
The PPARα antagonist MK886 
(0.3 µM) (open symbols) blocked 
the effects of WY (A) and 
fenofibrate (B) (n = 6) and 
restored nicotine-induced increase 
in sIPSCs. Symbols represent the 
mean±SEM. 
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Peroxisome Proliferator-Activated Receptor type alpha agonists as new 
therapeutic target for epilepsy: the translational study 
 
Puligheddu et al – in preparation 
 
Abstract:  
 
Nocturnal frontal lobe epilepsy (NFLE) is an idiopathic partial epilepsy with a family history in 
about 25% of cases with autosomal dominant inheritance [nocturnal frontal lobe epilepsy 
(ADNFLE)]. One of the key pathogenetic mechanisms is a “gain of function” of neuronal 
nicotinic acetylcholine receptors (nAChRs) containing the mutated α4 or β2 subunits. 
Fenofibrate, a common lipid-regulating drug, is an agonist at peroxisome proliferator-activated 
receptor alpha (PPAR-α) that is a ligand-activated transcription factor which negatively 
modulates β2*nAChR function. To test the clinical efficacy of adjunctive therapy with 
fenofibrate in pharmaco-resistant ADFNLE\FNLE patients, we first demonstrated the 
effectiveness of fenofibrate in a mutated (CHRNA4-S252F) mouse model displaying the disease 
genotype and phenotype in both in vitro and in vivo experiments. An add-on clinical protocol 
was subsequently implemented in a clinical setting. Here we show that a chronic fenofibrate diet 
markedly reduced the frequency of large IPSCs recorded from cortical pyramidal neurons in 
CHRNA4-S252F mice, and prevented nicotine-induced increase of IPSC frequency. Moreover, 
fenofibrate diet eliminated the differences observed between genotypes in the frequency of 
arousals from sleep under basal conditions in vivo. Accordingly, patients affected by FNLE, 
which were non-responders to traditional therapy, by means of adjunctive therapy with 
fenofibrate were found to display a significant reduction of seizure frequency. Furthemore, 
digital Videopolysomnographic recordings acquired in FNLE-subjects after 6 months of 
adjunctive fenofibrate therapy showed significant effects on motor-behavioural seizures control. 
Altogether, these observations pinpoint dysfunctional nicotinic receptors in NFLE, and provide a 
new perspective in both the investigation and the treatment of epilepsy. 
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Introduction 
 
Epilepsy is a common neurological disorder affecting 1% of the population worldwide [1]. Over 
the past decade, several idiopathic epilepsies have been shown single-gene inheritance, such as 
autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) [2]. Clinical features of 
ADNFLE are clusters of stereotypic episodes of arousal from sleep associated with dystonic 
neck, limb, and trunk movements that occur during stages 2-4 of non-rapid eye movement (non-
REM) sleep [3] [ 4], and are accompanied by severe sleep instability [5]. One of the key 
pathogenetic mechanisms underlying this inherited form of epilepsy is the “gain of function” of 
the neuronal nicotinic acetylcholine receptors (nAChRs) containing the mutated α4 or β2 
subunits. Consequently, a blockade of nAChRs might theoretically provide a therapeutic 
approach to treat ADNFLE.  
PPAR-α activation leads to phosphorylation of β2*-nAChRs with a consequent blockade of 
nicotine-induced activation of discrete neuronal populations in rodents [6] [7] [ Puligheddu et al., 
2013]. Synthetic PPAR-α agonists such as fibrates are already well established therapeutic 
options for the treatment of hyperlipidemia. Notably, fibrates exhibit similar anticonvulsant 
properties [ Puligheddu et al., 2013] to traditional ketogenic diet in an experimental model of 
epilepsy [9]. Indeed, we observed that PPAR-α agonists are protective against nicotine-induced 
seizures in behavioral and electroencephalographic (EEG) experiments in vivo, and in vitro 
abolish nicotine-induced spontaneous inhibitory post-synaptic currents (sIPSC) increased 
frequency in rodents (Puligheddu et al., 2013).  
Altogether, these observations prompted us to test both in vitro and in vivo the efficacy of a 
chronic diet with fenofibrate in a mutated mouse model displaying both disease genotype and 
phenotype. To optimize these results experiments were carried out in a previously described 
mouse model of NFLE (CHRNA4-S252F) [10]. Next, we set a clinical study based on the 
viability of fenofibrate in both ADFNLE and FNLE drug-resistant patients. To this aim, an add-
on protocol was implemented in a clinical setting. Based on our working hypothesis, we expect 
that fibrates via PPAR-α activation may be beneficial to the treatment of epilepsy. 
 
 
Materials and Methods 
 
Rationale and aim of the study 
The overall objective of this study was to test the efficacy of fenofibrate as an add-on therapy on 
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nocturnal frontal lobe epilepsy. In a mutated mouse model displaying the disease genotype and 
phenotype (CHRNA4-S252F) (10) we characterized electrophysiological and behavioral effects 
of a chronic diet with fenofibrate. Finally, we applied insights gained through this approach to 
examine the viability of fenofibrate in both ADFNLE and FNLE drug-resistant patients. To this 
aim, an add-on therapeutic protocol was implemented in a clinical setting. Methods used in this 
study that have been published previously in detail are included in the Supplementary Materials. 
  
2.1.Neurophysiology and behavior of NFLE mouse model (CHRNA4-S252F) 
 
Animals 
For all the experiments we used male, age-matched, wild type and heterozygous mice model of 
NFLE (CHRNA4-S252F) (10). The colony founders were obtained from the Mutant Mouse 
Regional Resource Center (MMRRC) and were donated to the MMRRC by Dr. Jim Boulter of 
UCLA. Mice were housed six per cage under a 12 h light/dark cycle (light on at 7:00 AM), in 
conditions of constant temperature (21 ±2°C) and humidity (60%), with food and water ad 
libitum. Animals were randomly assigned to the different experimental protocols: in vitro 
electrophysiology or electroencephalographic (EEG) recordings coupled with behavioral 
observations. 
 
Ethics Statement 
Experiments were performed in strict accordance with the EEC Council Directive of 24 
November 1986 (86/609). All efforts were made to minimize pain and suffering and to reduce 
the number of animals used. The experimental protocols were also approved by the Animal 
Ethics Committee of the University of Cagliari and by the Italian Ministry of Health. 
 
Chronic diet 
Both wild type (wt) and heterozygous Chrna4-S252F (mut) mice were randomly divided into 
diet treatment groups: (i) a standard diet (control group, Harlan Teklad Global 2016); (ii) a 0.2% 
fenofibrate diet (Fenofibrate from Sigma-Aldrich + Harlan Teklad Global 2016) (9)(8). Mice 
were fed diets for 14 days. For EEG and observational studies, diets started one week after 
electrode implantation (see below). 
 
Chronic EEG recordings 
Adult mice (PND > 90) were anesthetized with Equithesin (5 ml/kg, i.p.) and placed in a 
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stereotaxic apparatus (David Kopf, mod. 900). The skull was exposed and coated stainless steel 
electrodes were implanted in the right prefrontal cortex (from bregma (mm): anteroposterior 
+2.8, lateral 1.5, ventral to skull surface 1.5), and dorsal hippocampus (from bregma (mm): 
anteroposterior +2, lateral 2, ventral 2) (13).Ground and reference electrodes were positioned in 
the skull over the cerebellum. Electromyography (EMG) signals were recorded from two 
electrodes inserted in the neck musculature. All electrodes were connected to a five pin female 
socket secured to the skull with epoxy resin and covered with acrylic cement to improve 
retention. 
Baseline recordings were performed one week following surgical preparation. On day 15th after 
diet onset, the mice were connected to the recording system with a light-weight cable and a 
swivel allowing free movements in the cage. Digitally synchronized video/EEG recordings were 
acquired for 24 h. The signals were sampled at 256 Hz, bandpass-filtered (0.02-70 Hz) and 
recorded on a portable digital EEG polygraph (BQS 98 System Micromed). 
The digital data generated by the experimental settings were processed in Spike2 software 
analysis platform. Hippocampal activity was used, together with the EMG, to score an animal as 
being in wake, or sleeping in rapid eye movement (REM) or non-REM (14). For sleep-related 
micro-movement detection, the Root Mean Square of EMG signal was calculated(14). To 
minimize artifacts, the EMG signal peaks which fell on sleep states (non-REM, REM) were 
confirmed as sleep-related micro-movements with video-recording analysis carried out by an 
experimenter blind to mice genotype and treatment. 
 
2.2 In vitro electrophysiology 
The preparation of FCx slices and whole-cell patch clamp recordings from layer II/III pyramidal 
neurons was as described previously [Klaassen et al. 2006, Puligheddu et al. 2013]. Briefly, male 
mice ( PND 70-75 d were anesthetized with halothane and killed. A block of tissue containing 
the frontal cortex (FCx) was sliced in the coronal plane (300 µm) with a vibratome (Leica, 
Nussloch, Germany) in ice-cold low Ca2+ artificial cerebrospinal fluid (ACSF) containing (in 
mM): 126 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose 
(pH 7.3–7.4). Slices (two per animal) were transferred in a holding chamber and allowed to 
recover for at least 1 hr before being placed in the recording chamber and superfused with ACSF 
(32–34°C) saturated with 95%O2/5%CO2: FCx layer II/III pyramidal cells were identified 
visually with an upright microscope with infrared illumination, and whole-cell voltage-clamp 
recordings were made by using an Axopatch 200B amplifier (Molecular Devices, CA). All 
GABAA IPSC recordings were made with electrodes filled with an internal solution containing 
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the following (mM): 140 cesium-methylsulfonate, 0.2 EGTA, 5 NaCl, 10 HEPES, 2 Mg2ATP, 
0.25 Mg2GTP, pH 7.2–7.4. Experiments were begun only after series resistance had stabilized 
(typically 15–40 MΩ). Series resistance and input resistance were monitored continuously on-
line with a 4 mV depolarizing step (25 ms). Data were filtered at 2 KHz, digitized at 10 KHz, 
and collected on-line with acquisition software (Clampex 8.2, Molecular Devices, CA). Neurons 
were voltage-clamped at a membrane potential of 0 mV. All GABAA spontaneous IPSCs 
(sIPSCs) were recorded in presence of 2-amino-5-phosphonopentanoic acid (AP5; 100 µM), 6-
cyano-2,3-dihydroxy-7-nitro-quinoxaline(CNQX; 10 µM), to block N-methyl-D-aspartate- 
(NMDA), α-amino-3-hydroxy-5-methyl- 
isoxazolepropionicacid- (AMPA) mediated synaptic currents, respectively. As already described 
[Klaassen et al., 2006], there was no effect of this solution on the holding current of the 
pyramidal cells. 
 
2.3 Clinical study 
Patients: Twelve subjects affected by drug-resistant ADFNLE and FNLE have been enrolled for 
the purpose of this study from outpatients attending the Epilepsy Diagnostic and Sleep Disorders 
Center of Cagliari and Parma (Italy). Diagnosis were obtained on the basis of reports of patients 
or family members witnessing the event, from serial EEG, digital video-EEG plus Holter-EEG 
recordings, and genetic test when available. Only primary NFLE patients, both sporadic and 
genetic (with genetic test when available), were considered for  the study;  secondary forms were 
excluded by means of a high-resolution MRI, customized according to main electro-clinical 
information employing a 1.5-tesla ACS-NT unit (Philips Medical Systems, Best, The 
Netherlands). Drug resistance refers to the ILAE ( International League Against Epilepsy) 
definition of DRE (Drug Resistant Epilepsy) to achieve sustained seizure freedom (15). Informed 
consent, approved by Institutional Review Board, has been obtained from patients after a full 
explanation of the procedure. Recruited subjects  underwent adjunctive therapy with fenofibrate. 
The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 
1-methylethyl ester. Fenofibrate is usually indicated as adjunctive therapy to diet to reduce 
elevated LDL-Colestherol, Triglycerides, and Apo B, and to increase HDL-C in adult patients 
with primary hyperlipidemia or mixed dyslipidemia. In this protocol, fenofibrate is orally 
administered off label at 600  mg per day, three times a day, and for 6 months. Efficacy and 
safety adverse reactions have been documented and reported. Since changes in liver function are 
mostly the cause of discontinuation of fenofibrate treatment in 1.6% of patients in double-blind 
trials, blood examinations have been carried out every two months during the total observation 
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time. Furthermore, for safety survey both cardiologic examination and electrocardiogram (ECG) 
have been performed at the beginning (T0) and at the end (T1) of the study. Intermediate clinical 
observations (i.e., nocturnal seizure and sleep diary examination) have been performed every two 
months. Finally, in order to evaluate subjective clinical effects of fenofibrate, epileptic quality of 
Life questionnaire (EPI-QoL) (16) and Visual Analogic Scale (VAS)  quality of life have been 
filled by patients at T0 and T1.  
 
 
VPSG has been manually, double blinded, examined by two neurophysiologists expert in 
epilepsy and sleep disorders (GM and MP) and in agreement with clear-cut ictal epileptiform 
activity and stereotyped motor pattern, each VPSG motor event was classified as Minor Motor 
Events (MMEs), while paroxysmal arousals, tonic-dystonic seizures, hyperkinetic seizures, and 
prolonged motor behaviors were classified as Major Events  (MEs) (5). In both condition (T0 
and T1) the total distribution of MEs and MMEs was analyzed throughout total sleep time 
(NREM and REM sleep). 
 
Statistical analysis 
Due to non-parametric distribution of data, the analysis of seizure diary and VPSG epileptic 
events in NFLE patients before and after add-on FEN treatment was assessed by the non-
parametric Wilcoxon two-tailed signed rank test with paired comparison.  
Questionnaire Scores: Epileptic quality of Life questionnaire (EPI-QoL) and Visual Analogic 
Scale (VAS) scores acquired at T0 and T1 have been analyzed  by the non-parametric Wilcoxon 
two-tailed signed rank test with paired comparison. Cross-correlation between the variation of 
seizure frequency and quality of life scores after six months of add-on  FEN treatment has been 
calculated in order to evaluate an interdependency between this two conditions.  
Statistical significance was set at P < 0.05 (*) and test was performed using the calculation 
software GraphpadPRISM®. 
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Table 1. Clinical history of recruited subjects  
Demography, clinical and instrumental survey and traditional antiepileptic therapy of recruited 
subjects.  
 
Legend: ME major events, MME minor motor events, PA paroxysmal arousal, ENW epileptic 
nocturnal wondering. CBZ carbamazepine, LVT levetiracetam, OXC oxcarzepine,  LTG 
lamotrigine, VPA valproic acid. 
 
Subject Gender Age (y) Anamnestic nocturnal events 
Seizure 
onset         
age 
(years) 
Seizure 
frequency 
Cerebral 
NMR AED 
Routine wake–
EEG findings 
Pz1-BM M 34 ME, MME,PA,ENW 4 
Several 
time\day Normal 
VPA-Mg 
750 mg 
CBZ 600 
mg   
Sharp waves on 
right 
frontotemporal 
region 
Pz2-GL F 32 ME,MME, PA 10 Several time\day Normal 
LTC 3000  
mg         
VPA 1000 
mg 
Bilateral frontal 
high amplitude 
sharp waves 
Pz3-PP F 47 ME,MMEs 18 Several time\day Normal 
LVT 1000 
mg 
Sharp waves on 
right 
frontotemporal 
region 
Pz4-VP M 29 ME,MMEs 10 Several times/wk Normal 
LTG 200 
mg 
Bilateral 
aspecific fronto-
temporal slow 
waves 
Pz5-GR M 29 ME,PA,ENW MMEs 23 
Several 
times/wk Normal CBZ mg 
Bilateral 
aspecific fronto-
central slow 
waves 
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Pz6-PR M 41 ME,MMEs,ENW, PA 5 
Several 
time\day Normal 
OXC 600 
mg 
Bilateral frontal 
high amplitude 
sharp waves  
Pz7-BS-
ADNFLE F 24 ME,MMEs, PA 4 
Several 
time\day Normal 
OXC 600 
mg ndr 
Pz8-CT-
ADNFLE F 52 ENW,MMEs,PA 6 
Several 
time\day Normal   ndr 
Pz9-AP-
ADNFLE F 23 
ME,ENW,MMEs, 
PA 4 
Several 
time\mo Normal 
OXC  600 
mg 
Bilateral 
aspecific fronto- 
temporal slow 
waves 
Pz10-
MZ-
ADFNLE 
F 52 ME,ENW,MMEs, PA 6 
Several 
time\day Normal   ndr  
Pz11-CM M 35 ME, ENW,PA,MME 10 
Several 
times/wk Normal 
CBZ RM 
600 mg 
Bilateral frontal 
high amplitude 
sharp waves 
PZ12-IC F 29 ME,ENW,PA,MME 7 Several times/mo Normal 
CBZ 400 
mg  ndr 
Pz 13-BC M 37 ME,ENW,PA,MME 6 Several time\day Normal 
LVT 750 
mg ndr 
 
 
 
 
 
 
3. Results 
3.1. Neurophysiology and behavior of NFLE mouse model (CHRNA4-S252F)  
 
 
 
 
 
 
Chronic Administration of the Clinically Available PPARα agonist Fenofibrate reduced minor 
motor nocturnal  events.  
The results of the previous experiments prompted us to assess the efficacy of the clinically 
available PPARα agonist fenofibrate. Mice were randomly divided into three groups: (i) 
fenofibrate diet (FBR), (ii) control diet (CTRL) and (iii) fenofibrate washout diet (FBR-WO). 
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The fenofibrate containing diet was administered ad libitum for 14 days. FBR mice consumed a 
daily average of 3.6±0.1 g of food pellets, which approximately corresponds to 28–30 mg/kg 
fenofibrate per day. FBR mice were divided in two additional groups at the end of the treatment: 
one group received the PPARα antagonist MK886 15 min before the nicotine challenge, and the 
other received its vehicle. CTRL mice were fed with the control diet, identical and equicaloric 
but without fenofibrate. FBR-WO mice were fed for 14 days with a fenofibrate-containing diet, 
as FBR mice, and then fed with a control diet for additional 14 days to assess the effect of 
fenofibrate washout. In each animal EEG electrodes were implanted 7 days before the beginning 
of the treatments and nicotine was tested on the 15th day from the beginning of treatment (for 
FBR and CTRL mice) or on the 30th day (for FBR-WO mice). 
 
When nocturnal motor events were scored, two-way  ANOVA yielded a significant difference 
among groups (P<0.017) (Fig. 2). Post-hoc analysis revealed that nocturnal minor motor events 
FBR mice were significantly protected seizures when compared with CTRL animals ( p< 0.05).  
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3.2 Electrophysiology. 
It has been previously shown that the electrophysiological mechanism underlying 
epileptogenesis at the level of cortical circuits involves changes in synaptic activity onto 
pyramidal cells as key source of cortical EEG activity. We, therefore, examined the effect of 
acute activation of PPAR-α on inhibitory synaptic events of layer II/III pyramidal cells of the 
frontal cortex (FCx) in a mouse model of NFLE (CHRNA4-S252F) (1). Whole-cell voltage-
clamp recordings of spontaneous inhibitory post-synaptic currents (sIPSCs) were carried out 
from layer II/III pyramidal cells of wild type (wt) and heterozygous (mut) Chrna4-S252F mouse 
brain slices (1). Under basal conditions (Vholding=0 mV to isolate sIPSCs(1)), sIPSCs in wt and 
mut mouse pyramidal cells displayed a difference in the frequency of events larger than 50 pA 
(Figure 1A supplementary material; P < 0.05, unpaired t test with Welch's correction). We next 
examined the effects of nicotine (5 µM, 30 s) on sIPSCs recorded from wt and mut mouse 
pyramidal cells and, as previously described (1), we found a larger and longer effect in mut when 
compared to wt mice (Figure 1B supplementary material, P < 0.01, F30,180=6.62, two way RM 
ANOVA followed by Bonferroni). However, irrespective of the genotype, nicotine-induced 
effects were absent following an acute bath application of synthetic PPAR-α agonist WY14643 
(3 µM, 5 min, Figure 1B supplementary material, P > 0.05, F1,180=3.46, two way RM ANOVA 
followed by Bonferroni) in agreement with previous reports (2-4). We next chronically treated 
the mice with clinically available PPAR-α agonist, i.e. fenofibrate. Both wt and mut mice were 
fed a diet containing 0.2% w/w fenofibrate (4, 5) and were randomly divided into four groups, 
i.e. fenofibrate diet wt and mut mice, and control diet wt and mut mice. The fenofibrate diet was 
administered ad libitum for 14 days. Fenofibrate wt and mut mice consumed a daily average of 
4.61± 0.22 and 4.39 ± 0.13 g of food pellets, respectively, which corresponds to approximately 
300 mg/kg of fenofibrate per day. Experiments with mice chronically fed with fenofibrate 
confirmed that PPAR-α activation abolishes nicotine-induced increases in sIPSC frequency in 
FCx pyramidal neurons in both genotypes (Figure 1A, P > 0.05, F1,140=0.64, two way RM 
ANOVA followed by Bonferroni). Hence, nicotine-induced increase in sIPCS frequency was 
105.6±10.9% of baseline in fenofibrate wt mice (n = 7) and 84.6±10.9% of baseline in 
fenofibrate mut mice (n = 8). Remarkably, fenofibrate diet abolished the differences observed 
between genotypes in the frequency of IPSCs > 50 pA under basal conditions (Figure 1B, P > 
0.05, unpaired t test with Welch's correction). Hence, the frequency of sIPSCs > 100 pA 
recorded from fenofibrate mut mice was similar to control wt mice (Figure 1B, P > 0.05, 
unpaired t test with Welch's correction).  
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Figure 1. Effect of chronic diet with PPAR-α agonist fenofibrate in a mouse model of ADNFLE 
Voltage clamp recordings obtained from wt and mut mouse cortical layer II/III pyramidal cells. 
(A) Chronic fenofibrate (0.2% w/w for 14 days in food, FBR) fully suppressed nicotine-induced 
(5 µM perfused at arrow for 30 s) increase in sIPSC frequency in both wild type (wt, gray 
circles) and mutant Chrna4S252F (mut, red circles) mice. Notably, in FCx slices from mice fed a 
control diet (CTRL), nicotine increases sIPSCs frequency in layer II/III pyramidal neurons 
irrespective of the genotype. (B) The cumulative distribution plot of sIPSC frequency of neurons 
revealed that chronic fenofibrate reduced the occurrence of large sIPSCs in mut (mut FBR, 
dashed red line) mice with respect to mut mice fed a control diet (mut CTRL, solid red line). 
Notably, the frequency of larger sIPSCs in mut FBR mice was comparable to wt CTRL mice 
(solid gray line).  Representative recordings of the effect of chronic fenofibrate diet on sIPSCs 
from pyramidal cells at Vh = 0 mV are depicted on the upper part of panel A. Symbols represent 
the average±S.E.M. two- way ANOVA, *P<0.05. 
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Fig. S1. Cellular electrophysiology in a mouse model of ADNFLE: acute effects of a synthetic 
PPAR-α agonist. 
(A) Voltage clamp recordings obtained from wild type (wt) and mutant Chrna4S252F (mut) 
mouse cortical layer II/III pyramidal cells revealed an increased frequency of large sIPSCs in 
mut mice with respect to wt mice. The graph illustrates a nonlinear fit of Gaussian histogram of 
frequency distribution of events larger than 50 pA in wt and mut mice. In the inset the 
cumulative distribution plot of sIPSC frequency of neurons shows an increased frequency of 
events larger than 100 pA in mut mice when compared to wt mice. (B) The graph illustrates that 
in mouse FCx slices, nicotine (5 µM perfused at arrows for 30 s) increases sIPSCs frequency in 
layer II/III pyramidal neurons. Acutely, the PPARα agonists WY14643 (1 µM) fully suppressed 
nicotine-induced increase in sIPSC frequency in both genotypes. The light blue box represents 
the time of PPARα agonist perfusion. Representative recordings of the effect of nicotine, and of 
PPARα agonist, on spontaneous IPSCs from pyramidal cells at Vh = 0 mV are depicted on the 
upper part of panels A and B. Symbols represent the average ± S.E.M. two- way ANOVA, 
*P<0.05. 
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3.2. Clinical protocol for drug-resistant ADNFLE\NFLE patients 
In order to study the effect of an adjunctive therapy with fenofibrate, patients affected by 
ADNFLE\FNLE, and   non-responders to traditional therapy, were recruited.  Clinical data, brain 
nuclear magnetic resonance, and routine wake–EEG findings of NFLE subjects under traditional 
antiepileptic treatment are summarized in Table S1. Eight subjects presented nocturnal motor 
events since childhood, while the mean duration of paroxysmal motor events during sleep was 
approximately 3 years before diagnosis in the remaining subjects. Four subjects reported a 
family history of epilepsy, with confirmed α2β2 mutation, and eight  subjects described 
parasomnias or nocturnal motor events in first-grade relatives. None of the subjects displayed 
either perinatal hypoxia, or childhood febrile convulsions, or mild head injury and diurnal 
seizures were rarely reported. Neurologic examinations were unremarkable and customized MRI 
were normal for all subjects.  
Protocol 
The fenofibrate add-on therapy consisted of 600 mg per day for six months.  Among the patients, 
two (ADNFLE) subjects refused (signed declaration) traditional antiepileptic (AE) therapy, and 
fenofibrate was administered as monotherapy. Patient 12 (BC) dropped out from the study 
because of increased hepatic enzymes above normality range during the first month of therapy, 
though they immediately returned to normal ranges after interruption. After six months of add-on 
therapy (T1-FEN), results of quality of life tests and daily seizures diaries were collected. 
According to subjective seizure diaries, which were based upon subject and bed-partner reports, 
eight out of eleven subjects were seizure free, whereas the remaining 3 reported a reduction 
larger than 75% of major events (Figure 2A, P = 0,002). Table 1 shows seizures rate change 
calculated according to Labar rule (Labar, Murphy, & Tecoma, 1999). Figure 2 (B-C) displays 
the Wilcoxon test results with regard to Visual Analogic Scale (VAS) and epileptic quality of 
Life questionnaire  (EPI-QoL) . Although none of subjects displayed a severe discomfort in 
relation to their pathological condition, both the scores showed a significant improvement after 
six months of add-on therapy (P =0,0186 and P=0,022 respectively) (Table 1 and Figure 2 B-C). 
Nonetheless, no significant correlation between EPI-QoL improvement and reduction in seizures 
frequency was unveiled (data not shown). 
3.3.2  Videopolisomnograpy (VPSG) recordings at T1-FEN . 
A total of 328 epileptic motor events were counted during VPSG recordings of NFLE subjects at 
T0. The prevalence of seizures (approximately 85%) was recorded during NREM sleep in 
agreement with previous reports (Parrino et al., 2012). The 225 epileptic events (68% of total 
NREM sleep seizures) were classified as Minor Motor Events (MMEs), and they mainly 
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occurred during stage 2 of NREM sleep (N2). The remaining  seizures (32% of total NREM 
sleep seizures) were classified as Major Events (MEs) (28 events). 
After 6 month of fenofibrate add-on therapy (T1-FEN), VPSG recording displayed a significant 
decrease of the total number NREM sleep seizures (Figure 2 D, P=0,002). In detail, a reduction 
of MEs (Figure 2E, P=0,021) and MMEs (Figure 2F p=0,0087)  was evident . Table 2 shows the 
hourly indexes of all VPSG epileptic events and of the  ME and MME subgroups at T0 and T1 . 
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Tab1 Effect of add-on Fenofibrate treatment on reported seizures and quality of life tests. 
 
Single subjects seizures report (T0) and Labar seizures rate change after 6 month of add-on 
fenofibrate treatment ((T0 and TT1). Subjects were administered a Visual Analogic Scale (VAS) 
and epileptic quality of life questionnaire  (EPI-QoL) and the relative score change is displayed 
after treatment. Wilcoxon two-tailed signed rank test with paired comparison (*P<0.05; ** 
P<0,001)  
M: male; F: female  
 
 
 
Subject Gender Age (y) 
N. seizures (reported 
diary)  
[% change  after six  
month off add-on 
FEN] 
      EPIQoL T0                     
[% change  after 
six month of add-
on FEN] 
VAS T0                 
[% change after 
six month of 
add-on FEN] 
Pz1-BM-NFLE M 35 92(-97,83) 184(19,02) 5(28,6) 
Pz2-GL-NFLE F 32 25(-96) 124(62,10) 5(0) 
Pz3-PP-NFLE F 47 36(-100) 193(25,90) 5(37,5) 
Pz4-VP.NFLE M 29 104(-98,07) 216(12,03) 5(33,3) 
Pz5-GR-NFLE M 29 38(-89,47) 216(15,74) 5(44,4) 
Pz6-PR.NFLE M 41 93(-100) 189(20,63) 2,5(58,3) 
Pz7-BS-
ADNFLE F 24 252(-90,48) 196(20,41) 5(33,3) 
Pz8-CT-
ADNFLE F 52 24(-87,5) 236(3,28) 5(0) 
Pz9-AP-
ADNFLE F 23 168(-98,21) 240(-5,91) 9(0) 
Pz10-MZ-
ADFNLE F 52 24(-100) 220(-3,48) 5(28,6) 
Pz11-CM.NFLE M 35    240( 0,5) 5(0) 
Wilcoxon test  p =0,002** p=0,0186 * p=0,022 * 
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Tab2 Effect of add-on Fenofibrate treatment on VPSG recorded seizure. 
 
 
Subjects Gender Age (y) 
VPSG 
T0   
total N 
of 
Seizures 
VPSG 
T1-FEN     
total N 
of 
Seizures 
VPSG 
T0    
N of 
MEs  
VPSG 
T1-FEN    
  N of 
MEs  
VPSG 
T0  
  N of 
MMEs  
VPSG 
T1FEN        
N of 
MMEs  
Pz1-BM-NFLE M 35 48 18 1 0 47 18 
Pz2-GL-NFLE F 32 37 5 1 0 36 5 
Pz3-PP-NFLE F 47 35 16 6 0 24 14 
Pz4-VP.NFLE M 29 36 17 0 0 36 17 
Pz5-GR-NFLE M 29 10 3 1 0 6 1 
Pz6-PR.NFLE M 41 63 31 0 0 59 30 
Pz7-BS-ADNFLE F 24 36 31 15 3 19 27 
Pz8-CT-ADNFLE F 52 25 14 0 0 18 9 
Pz9-AP-ADNFLE F 23 33 22 2 0 26 15 
Pz10-MZ-ADFNLE F 52 14 1 0 0 10 1 
Pz11-CM-NFLE M 35 8 2 2 0 6 2 
Wilcoxon test   p=0,002*  p=0,021*  p= 0,0087** 
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Fig 4A. Effect of fenofibrate add-on teraphy on seizures reported diary three months before (T0) 
e after treatment (T1-FEN). 
 
 
 
 
 
Fig 4B. Effect of fenofibrate add-on teraphy on total seizures recorderd during VPSG before 
(T0) e after treatment (T1-FEN). 
 
N
 o
f s
ei
zu
re
s
T0 Diary report T1-FEN Diary report
0
50
100
150
***
N
 o
f s
ei
zu
re
s
VPSG T0_E tot VPSG T1-FEN_tot E
0
10
20
30
40
*
 72 
 
Fig 4C. Effect of fenofibrate add-on teraphy on Major Events recorderd during VPSG before 
(T0) e after treatment (T1-FEN). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4D.  Effect of fenofibrate add-on teraphy on Minor Motor Events recorderd during VPSG 
before (T0) e after treatment (T1-FEN). 
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Fig. 5 results of  visual Analogic scale and EpiQoL before (T0) e after treatment (T1-FEN). 
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Discussion 
 
Nowadays, a beneficial therapy for Nocturnal Frontal Lobe Epilepsy (FNLE) still represents a 
significant clinical need, as carbamazepine, the most efficacious drug for FNLE, completely 
abolishes the seizures only in ~20% of patients, and reduces the seizures only in 48% [12], thus 
leaving approximately one third of patients without therapeutic response. The major finding of 
the present study is the clinical efficacy of the PPAR-alpha agonist fenofibrate add-on therapy in 
NFLE patients, which exhibited a remarkable seizures reduction with a good control of the 
disease. We also extend the evidence for the action of PPAR-alpha as negative modulator of 
nAChRs to a mutated mouse model of NFLE, which displays both the genotype and the 
phenotype of the human disease.   
Several observations support our conclusions. First, the patients and their bed-partners reported 
in daily diary of seizures a significant reduction of these events together with a consistent 
improvement in their quality of life, as indexed by EpiQoL test and VAS. Secondly, the 
instrumental VPSG nocturnal recordings supported that the efficacy of the add-on therapy is 
evident not only for major motor events, but also for minor motor events. Notably, minor motor 
events seriously affect the development of the disease and disrupt sleep-architecture, though they 
are totally unperceived by the subjects. The observation that a single instrumental analysis, 
though compared with a single night under basal conditions, substantiated the six month daily 
reports in the diary of seizures filled by the patients and their bed-partners strongly underscores 
the efficacy of this add-on therapy. In addition, while traditional antiepileptic treatment for this 
type of epilepsy determines a partial (about 25%) reduction of objective VPSG seizures, sleep 
instability remains pathologically enhanced, and is associated with persistence of daytime 
sleepiness [2]. Third, a significant reduction of minor motor events is also evident during the 
overnight recordings in mutated mice chronically fed with the fenofibrate diet. Notably, minor 
motor events are related to a loss of cortical inhibition, which is secondary to arousal triggered 
by internal epileptiform stimuli of innate motor patterns generated by central pattern generators 
[14-15] and might occur in either presence or absence of an epileptiform discharge [15]. The 
observation that fenofibrate diet reduces minor motor events and arousability induced by 
epileptic stimuli in the mouse model of the disease demonstrates a helpful control on seizure 
activity, epileptiform internal stimuli and, consequently, ameliorates sleep instability by reducing 
the triggered arousability. Fourth, ex vivo both acute and chronic PPAR-alpha activation reduces 
nicotine-induced enhancement of frequency of sIPSCs in FCx pyramidal neurons irrespective of 
the genotype. This increase has been hypothesized to trigger network synchrony and ictal 
activity [3]. Notably, the observation that mutated mice exhibit an augmented frequency of larger 
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sIPSCs (> 100 pA amplitude), which following the fenofibrate diet becomes comparable to wild 
type mice, supports the hypothesis that network synchrony and ictal activity might account for 
cellular and behavioural expressions of the disease. Lastly, these observations support our 
hypothesis that PPAR-alpha activation might prevent/reduce the loss of cortical inhibition, as 
previously demonstrated in a pharmacological model of the disease (chapter 2 and ref  [13].   
The conclusions that PPAR-alpha might be a key regulator of neuronal activity through the 
modulation of nAChR functional properties, and that these effects might be therapeutically 
exploited, are in agreement with the fact that nAChRs play a major role in diverse idiopathic 
and/or genetically determined forms of epilepsy. Remarkably, a dysfunction of the brain 
cholinergic systems is hypothesized to underlie diverse disorders, including insomnia, mania and 
depression [15][16][17]. In agreement, we observed a significant improvement of quality of life 
in our group of NFLE patients. Remarkably, the finding that such an effect does not correlate 
with seizure control might support not only the cholinergic hypothesis of mood disorders, but 
also the therapeutic potential of PPAR-alpha agonists as antidepressant-like drugs [18][19].   
Nevertheless, given that the patients were not aware of any possible antidepressant-like property 
of fenofibrate add-on therapy, which would have contributed to a placebo effect, the significant 
efficacy score reported, and finally yet importantly, the patient determination to continue taking 
the fenofibrate even after the completion of the study, support the preclinical findings suggestive 
of an independent role of fenofibrate on mood regulation. 
Further studies on macro and micro- sleep architecture are certainly required in order to verify 
this final hypothesis.  
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Final Conclusion and “take home” messages.  
 
A therapy for NFLE and ADNFLE represents a significant clinical need.  
 
The recently discovered novel mechanism of regulation of nAChRs by PPAR-alfa may 
represent a new therapeutic avenue for medications aimed at diseases such as NFLE and 
ADNFLE, where “a gain of function” of nAChR is responsible for the cardinal symptoms.  
 
The use of available animal models of ADNFLE together with advanced neurophysiological 
and brain-imaging techniques in humans offered an extraordinary opportunity to study a 
potentially important therapeutic strategy, which, noteworthy, may rely on drugs already 
clinically utilized in humans.  
 
The conclusions that PPAR-alpha might be a key regulator of neuronal activity through 
the modulation of nAChR functional properties, and that these effects might be 
therapeutically exploited, are in agreement with the fact that nAChRs play a major role in 
diverse idiopathic and/or genetically determined forms of epilepsy.  
 
Remarkably, a dysfunction of the brain cholinergic systems are hypothesized to underlie 
diverse disorders, including insomnia, mania and depression In agreement, we observed a 
significant improvement of quality of life in our group of NFLE patients. Indeed, the 
finding that such an effect does not correlate with seizure control might support not only 
the cholinergic hypothesis of mood disorders, but also the therapeutic potential of PPAR-
alpha agonists as antidepressant-like drugs  
 
Furthermore, one of the specific features of NFLE is the relationship with sleep rhythms 
and seizures. Our results will also support our working hypothesis that fibrates might 
represent an innovative therapeutic avenue not only for FNLE and ADNFLE, but also for 
other sleep disorders. 
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